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PART I
Structural Insights into Epigenetic Regulation Revealed by Crystal Structures of
The Histone Methyltransferase SMYD2

CHAPTER 1 General Introduction

1.1 Epigenetic regulation
Epigenetics can be described as the study of heritable changes in gene activity
without changing the primary DNA sequence, such as DNA methylation and histone
post-translational modification5. Epigenetic regulation is emerging as one of the most
important research areas since it is greatly involved in a variety of biological processes
such as signal transduction, cell cycle control, and stress response6. Abnormal epigenetic
regulation has been linked with various diseases such as diabetes, heart disease, cancer
and Alzheimer’s disease7-9.

1.1.1 Direct vs. indirect epigenetic mechanisms
Epigenetic regulation can be divided into two groups according to the mode of
epigenetic modifiers involved in the regulation process. The most common type is the
direct regulation, in which epigenetic regulators such as histone acetyltransferase and
DNA methyltransferase act directly on chromatin to alter chromatin structure and
subsequent gene expression. However, some epigenetic regulators can have dual
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functions so that besides directly affecting chromatin, they can interact with proteins that
are involved in the regulation of epigenetic gene, such as sequence-specific DNA
transcription factors. In addition, some histone-modifying enzymes can directly modify
transcription factors involved in gene regulation. For example, the histone lysine
methyltransferase SET7/9 regulates the expression of p53 target genes through direct
methylation on p5310. Similarly, the histone lysine methyltransferase SMYD2 represses
the expression of the estrogen receptor target genes via ERα methylation11.

1.1.2 Epigenetic signaling
Growing evidence indicates a coplay between epigenetic mechanisms and
signaling pathways that establish transcriptional programs. Signaling pathways affect
critical components of the epigenetic machinery; on the other hand, the epigenetic
mechanisms are involved in signaling transduction regulation6. However little is known
about molecular mechanisms regulating the crosstalk between signal transduction and
epigenetic regulation, or the relationship between chromatin-associated proteins and
essential signaling pathways. It is anticipated that studying the connection between cell
signaling and epigenetic regulation will assist us in comprehending the intricate process
of cellular transcriptional changes caused by the presence of external and internal
signals.

1.1.3 Histone methylation

3

Posttranslational modifications of histones represent an essential epigenetic
regulatory mechanism, which affects the chromatin structure and DNA accessibility,
thereby controls gene transcription. There are many types of histone modifications
including acetylation, methylation, phosphorylation, ubiquitination, glycosylation,
sumoylation, ADP-ribosylation and carbonylation
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. These modifications have been

demonstrated to be essential for cell growth and development. Among these
modifications, histone methylation regulates the fundamental processes such as
heterochromatin

formation,

X

chromosome

transcriptional regulation and DNA repair

13-16

inactivation,

genomic

imprinting,

. Disrupting the balance of histone

methylation can lead to the altered expression of genes involved in tumorigenesis
including proto-oncogenes and cell cycle regulators. Although the potential impact of
histone methylation on health is self-evident, there are still many gaps in knowledge
regarding to the enzymes that are responsible for histone methylation.

1.2 SMYD proteins
1.2.1 Overview
Members of the SET and MYND domain-containing (SMYD) family of proteins
possess histone lysine methyltransferase capacity and are involved in the transcriptional
control of cell differentiation and cell proliferation17-21. The SMYD protein family
consists of five proteins (SMYD1–5) which are grouped based on the presence of two
conserved domains (MYND and SET domains)19(Figure 1). The MYND domain is a zinc
finger motif that is involved in protein−protein interaction22. The SET domain is an
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evolutionarily conserved motif responsible for adding methyl groups to lysine residues of
protein using S-adenosylmethionine (AdoMet) as donor substrate. The function of the Cterminal domain (CTD) is still poorly understood. In all known SMYD structures, the
CTD adopts a helix-turn-helix structure, which is similar to the architecture of the
tetratricopeptide repeat (TPR) motifs. Since the TPR motifs mediate specific proteinprotein interactions and the assembly of multi-protein complexes, the structural similarity
between the CTD and the TPR motifs may suggest a potential function for the CTD as a
protein-protein interaction module.

Figure 1. Schematic diagram of SMYD proteins domain structures and their related
functions.

1.2.2 SMYD proteins in heart and muscle development
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SMYD proteins are essential in the transcriptional regulation of cell
differentiation and cell proliferation17, 18, 20, 21, 23-26. Evidence for a critical role of SMYD
proteins during organ development was first shown by the constitutive knockout of
SMYD1 in mice, resulting in early embryonic lethality due to disruption of cardiac
differentiation and morphogenesis. Similar results have been observed in zebrafish that
knockdown of SMYD1 causes severe myofibrillar disorganization and malfunction of
cardiac and skeletal muscles23, 27. Subsequent reports have indicated that SMYD proteins
are indeed critical regulators of cardiac and skeletal muscle development28-31. In mice,
SMYD2 methylates Hsp90 forming a complex with titin, a sarcomeric protein, to protect
myocyte organization32, 33.

1.2.3 SMYD proteins in cancers
Mounting evidence suggests that SMYD proteins play important roles in cancer
development. Oncogenic activity of SMYD3 has been observed in many human cancers,
such as breast cancer, hepatocellular cancer, and colorectal carcinomas26. SMYD4 has
been identified as a potential tumor suppressor involved in breast cancer development.
Expression levels of SMYD4 are significantly lower in breast cancer cells than healthy
mammary cells. Disruption of one allele of the SMYD4 gene through chromosome
translocation resulted in tumorigenesis34. High level of SMYD2 expression have been
observed in a number of human cancers35, 36. Overexpression of SMYD2 caused changes
in expression of genes associated with cell cycle regulation and transcription regulation.
A recent study has shown that SMYD2 assists in maintaining the self-renewal activity of
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MLL-AF9-induced acute myeloid leukemia37. SMYD2 has also been shown to represses
transcriptional p53 activity by lysine methylation (Lys370), exerting an oncogenic and
drug resistance action through inhibition of p53-mediated cell death pathways38. In
addition to p53 methylation, studies showed that the retinoblastoma tumor suppressor
(RB), a central cell cycle regulator and tumor suppressor, can be methylated by SMYD2,
which regulates the RB activity during cell cycle progression, cellular differentiation, and
in response to DNA damage39. In agreement with these observations, SMYD2 recently
has been reported as a cancer-promoting gene through activation or overexpression in
esophageal squamous cell carcinoma36. Together, these findings suggest the therapeutic
potential of SMYD proteins in a range of human cancers.

1.3 Estrogen signaling
1.3.1

Overview

Estrogen signaling pathway controls cellular responses to estrogen and regulates
gene transcription in diverse developmental processes40. Estrogen signaling is mediated
by two estrogen receptors, ERα and ERβ, which are ligand-activated transcription factors
and belong to the nuclear receptor superfamily41. Upon activation by estrogen, estrogen
receptors form a dimer, which binds directly to the estrogen responsive elements (EREs)
and then activates downstream gene expression

41-43

(Figure 2). Estrogen binding also

induces a conformational change in the receptors, which allows the recruitment of a
number of coregulators, including coactivators and corepressors, for specific regulation
of gene activation and repression41.
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Figure 2. Classical estrogen signaling pathway.
Dysregulation of estrogen signaling can lead to a number of human diseases,
including a variety of human cancers such as breast, ovarian, colorectal, prostate, and
endometrial cancers, and also other diseases such as endometriosis, fibroids, and
cardiovascular disease44. Thus, detailed understanding of the complex regulatory
machinery underlying estrogen signaling has become extremely important.

1.3.2 Epigenetic regulation of estrogen signaling
Regulation of the transcriptional response of estrogen stimulation relies on both
direct and indirect epigenetic signaling. Epigenetic regulators perform posttranslational
modification either directly on histones or indirectly on estrogen receptors to alter ER
target gene expression. For example, in response to hormone stimulation, the coactivator
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complex p300/CBP gets recruited to the promoters of estrogen responsive genes where it
acetylates local histones causing nucleosomal destabilization and recruitment of
transcription factors45. In addition, the recruitment of the mixed lineage leukemia histone
methylases (MLLs) is required for ERα transcriptional activity, and the knockdown of
MLLs abolishes H3K4 trimethylation resulting in significant suppression of the estrogeninduced HOXC13 activation46.
Besides the direct action on chromatin, some epigenetic enzymes regulate
estrogen signaling via posttranslational modification of the estrogen receptors. Such
modifications include acetylation, phosphorylation, methylation, sumoylation and
ubiquitylation. These modifications are associated with distinct biological outcomes of
ER-mediated signaling. Acetylation of ERα on K266/268 in the hinge region enhanced
the DNA binding and transactivation activities of ERα, whereas acetylation on K302/303
represses target gene expression. In addition, ubiquitination at K302 and sumoylation at
K266/268 have also been shown to affect estrogen receptor stability and activity

47-49

.

Patients who have ERα S118 and/or S167 phosphorylated often have a better response to
tamoxifen (Tam) therapy, while phosphorylation of S305 often results in tamoxifen
resistance50. Recent identification of several ERα methylation sites has further expanded
our knowledge in the role of the posttranslational modification in ER regulation. SET7/9
regulates ERα activity and stability via methylation on K30251. K260 of ERα was
discovered as the target of protein arginine methyltransferase 1 (PRMT1) in the
cytoplasm of normal and malignant epithelial breast cells52. We recently showed that the
histone H3K4/H3K36 methyltransferase SMYD2 regulates ERα transactivation by K266
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methylation, which attenuates ERα chromatin recruitment and prevents ERα target gene
activation under an estrogen-depleted condition11. This finding identified a previously
undefined inhibitory methylation event, contributing to a substantial body of evidence
that posttranslational modifications of ERα provide complex and combinatorial
regulation that assures the protein to be tightly regulated and coordinating the appropriate
transcriptional response. Moreover, it highlights the importance of uncovering the
structural basis of the SMYD2-mediated ERα methylation, as a necessary prerequisite of
discovering small molecules that could fine-tune ERα activity or stimulate the restoration
of normal ERα-dependent transcription programs. These findings, together with other
epigenetic regulatory mechanisms38, demonstrate an intricate relationship between
epigenetics and estrogen signaling that function cooperatively to specify ER
transcriptional consequences.

1.4 Concluding remarks and objectives
Epigenetic regulation plays an essential role in many biological processes,
including cell-cycle regulation, development and differentiation. Since the dysregulation
of SMYD proteins has been found in various diseases, these proteins have rapidly
emerged as attractive therapeutic targets for drug discovery. There has been a growing
interest in various mechanisms that involve epigenetic regulation, including modulation
of SMYD proteins activities. However, little is known about the mechanisms underlying
the function regulation of SMYD proteins. Structural studies have revealed new insights
into the mechanisms behind the lysine methylation machinery and possible allosteric
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regulation that may involve conformational flexibility. Future studies that can further
uncover the molecular mechanisms of SMYD proteins will not only help us better
understand the mechanism of the epigenetic inheritance, but also provide us great
benefits in the development of alternative therapeutic strategies.
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CHAPTER 2
Crystal Structures of Histone and p53 Methyltransferase SMYD2 Reveal A
Conformational Flexibility of The Autoinhibitory C-terminal Domain

*Published in PLoS ONE 2011;6(6):e21640. doi:10.1371/journal.pone.0021640.
All authors agreed with including their work in this dissertation.

Abstract
SMYD2 belongs to a new class of chromatin regulators that control gene
expression in heart development and tumorigenesis. Besides methylation of histone H3
K4, SMYD2 can methylate non-histone targets including p53 and the retinoblastoma
tumor suppressor. The methyltransferase activity of SMYD proteins has been proposed to
be regulated by autoinhibition via the intra- and interdomain bending of the conserved Cterminal domain (CTD). However, there has been no direct evidence of a conformational
change in the CTD. Here, we report two crystal structures of SMYD2 bound either to the
cofactor product S-adenosylhomocysteine or to the inhibitor sinefungin. SMYD2 has a
two-lobed structure with the active site located at the bottom of a deep crevice formed
between the CTD and the catalytic domain. By extensive engagement with the
methyltransferase domain, the CTD stabilizes the autoinhibited conformation of SMYD2
and restricts access to the catalytic site. Unexpectedly, despite that the two SMYD2
structures are highly superimposable, significant differences are observed in the first two
helices of the CTDs: the two helices bend outwards and move away from the catalytic
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domain to generate a less closed conformation in the sinefungin-bound structure.
Although the overall fold of the individual domains is structurally conserved among
SMYD proteins, SMYD2 appears to be a conformational “intermediate” between a
closed form of SMYD3 and an open form of SMYD1. In addition, the structures reveal
that the CTD is structurally similar to tetratricopeptide repeats (TPR), a motif through
which many cochaperones bind to the heat shock protein Hsp90. Our results thus provide
the first evidence for the intradomain flexibility of the TPR-like CTD, which may be
important for the activation of SMYD proteins by Hsp90.

Introduction
Covalent histone modifications represent an important regulatory mechanism
controlling gene transcription, essential for normal growth and development16. Disrupting
the balance of histone modifications can lead to the altered expression of genes involved
in tumorigenesis including proto-oncogenes and cell cycle regulators53; however, little is
known about how the enzymes that control histone modifications are regulated
posttranslationally. Members of the SET and MYND domain containing (SMYD) family
of proteins possess histone lysine methyltransferase capacity and have been shown to be
involved in the transcriptional control of cell differentiation and cell proliferation53-57.
The SMYD protein family consists of five proteins (SMYD1–5) that share about 30%
sequence identity with each other and are grouped based on the presence of two
conserved domains (MYND and SET domains)55. The MYND domain is a zinc finger
motif that is involved in protein−protein interaction22. The SET domain is an
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evolutionarily conserved motif consisting of about 130 amino acids that is responsible for
adding methyl groups to lysine residues of proteins using S-adenosylmethionine
(AdoMet) as a donor substrate.

Evidence for a critical role of SMYD proteins during organ development was first
shown by the constitutive knockout of SMYD1, resulting in early embryonic lethality due
to disruption of cardiac differentiation and morphogenesis54. Subsequent reports have
further indicated that SMYD proteins are indeed critical regulators of cardiac as well as
skeletal muscle development29, 56, 58-60. Despite being highly expressed in heart and brain,
a specific functional role for SMYD2 in these organs has not been well characterized53, 59.
Overexpression of SMYD2 has been shown to cause changes in expression of genes
associated with chromatin remodeling, cell cycle, and transcription regulation, indicating
that this protein may function as a transcriptional regulator by methylating H3 K4 and
participates in cell cycle regulation and cell growth55. Interest in SMYD2 has grown
significantly because of recent reports indicating that SMYD2 repress transcriptional p53
activity by lysine methylation (Lys370), exerting an oncogenic and drug resistance action
through inhibition of p53-mediated cell death pathways38. In addition to p53 methylation,
a new study showed that the retinoblastoma tumor suppressor (RB), a central cell cycle
regulator and tumor suppressor, can also be methylated by SMYD2 at lysine 860, which
regulates the RB activity during cell cycle progression, cellular differentiation, and in
response to DNA damage61. In agreement with these observations, SMYD2 recently has
been shown to act as a cancer-promoting gene through activation or overexpression in
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esophageal squamous cell carcinoma36. These studies thus support a role for SMYD2 in
the regulation of proliferation and in tumor progression, which underscores the
importance of elucidating the regulation of SMYD2 activity.

The molecular chaperone Hsp90 plays an important role in the folding, activation,
intracellular transport, and assembly of a broad range of client proteins, specifically
chaperoning molecules involved in signal transduction and cell cycle regulation62.
Mounting evidence showed that Hsp90 is also involved in transcriptional regulation and
epigenetic inheritance by interacting with epigenetic proteins that function in chromatin
remodeling and histone modifications63, 64. Based on the ability of Hsp90 to stimulate the
activity of SMYD proteins, recent studies have characterized SMYD proteins as new
clients of Hsp9055, 64; however, the critical questions regarding how Hsp90 activates
SMYD proteins remain poorly understood. Previous studies suggested that the
methyltransferase activity of SMYD proteins is suppressed by an autoinhibited
conformation maintained by the CTD, a helix bundle C-terminal to the catalytic SET
domain that is conserved and unique in SMYD proteins65, 66. It has been proposed that the
intra- and interdomain bending of the CTD may be central for the activation of SMYD
proteins by Hsp9066. In this paper, we report two crystal structures of full-length SMYD2
in complex with the methyltransferase inhibitor sinefungin (SFG) and the cofactor
product S-adenosylhomocysteine (AdoHcy). Our studies demonstrate for the first time
the intradomain flexibility of the CTD and reveal the structural resemblance of the
autoinhibitory CTD to tetratricopeptide repeat (TPR) motif, which suggest a mechanism
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for the Hsp90-mediated activation of SMYD proteins. Our findings therefore contribute
to the understanding of the mechanism that regulates the activity of SMYD proteins in
early heart development and tumorigenesis.

Materials and Methods
Protein Preparation
Protein purification was performed essentially as described previously65. Briefly,
mouse SMYD2 was cloned into the pSUMO vector (LifeSensors), with an N-terminal
His6-SUMO tag. Recombinant SMYD2 was then transformed into Escherichia coli for
protein expression. The transformants were grown to an OD600 (optical density at 600
nm) of 0.4 at 37°C in 2 L LB medium, and then induced with 0.1 mM isopropylthio-β-Dgalactoside at 15°C overnight. The cells were harvested, and lysed by French Press. The
soluble fraction was then subjected to a series of chromatography purification by an
AKTA purifier system (GE healthcare), and the His6-SUMO tag was cleaved off with
yeast SUMO Protease 1. SMYD2 proteins were finally purified to apparent homogeneity
and concentrated to 10−20 mg/ml in 20 mM Tris−HCl (pH 8.0), 150 mM NaCl, 1 mM βmercaptoethanol, and 5% glycerol.

Crystallization and data collection
Prior to crystallization, SMYD2 (10 mg/ml) was incubated with 2 mM AdoHcy or
sinefungin at 4 °C for 2 h. The binary complex of SMYD2−AdoHcy or
SMYD2−sinefungin was then crystallized by hanging drop vapor diffusion at 20 °C, with
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15% polyethylene glycol 8000, 50 mM NaCl, 100 mM Tris, pH 8.0. Crystals typically
appeared within 1 day, achieved their full size in a week. X-ray diffraction data from
single crystals were collected at beamline 21IDD at the Advanced Photon Source
(Argonne, IL) and were then processed and scaled using the program HKL200067. The
crystals belong to the orthorhombic space group P212121 and contain one molecule in the
asymmetric unit (Table 1).

Structure determination and refinement
The crystal structure of SMYD2 in complex with AdoHcy was solved by the
single-wavelength anomalous diffraction (SAD) method using three intrinsic zinc ions.
Initial phases were obtained using the program SOLVE68, which was able to identify all
three zinc sites with a figure of merit of 0.329 in the resolution range 20−2.1 Å. After
density modification with the program RESOLVE68, the resulting electron density map is
interpretable. With the modified phases, automated model building was carried out by
RESOLVE, which built 80% of the protein residues including side chains. The model
was then completed and improved by alternating cycles of manual model building and
refinement using COOT69 and BUSTER70. The final refined model is well ordered with
the exception of the first two residues and the last residue. Because of isomorphism of
crystals (Table 1), the crystal structure of SMYD2 in complex with sinefungin was solved
by rigid-body fitting of the SMYD2−AdoHcy model followed by manual model building
and refinement as described above. The final models were analyzed and validated with
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PROCHECK71. All figures of 3D representations of the SMYD2 structures were made
with PyMOL (www.pymol.org).

Protein Data Bank accession number
Coordinates and structure factors have been deposited in the Protein Data Bank
with accession number 3QWV and 3QWW for SMYD2−AdoHcy and SMYD2−SFG,
respectively.

Results and Discussion
SMYD2 structure with the TPR-like CTD
Two crystal structures of full-length SMYD2 in complex with the cofactor
product AdoHcy and the methyltransferase inhibitor sinefungin have been determined at
2.1 Å and 1.8 Å by zinc single-wavelength anomalous dispersion (Table 1). Similar to
SMYD1 and SMYD365, 66, SMYD2 has a multidomain structure that folds into two lobes
with overall dimensions of approximately 65 Å x 40 Å x 55 Å (Figure 3). Although the
overall fold of their individual domains is structurally conserved, the SMYD family
proteins differ dramatically in the relative orientation between the N- and C-terminal
lobes. Detailed description of the structural differences will be addressed later in the
article. The N-terminal lobe (residues 3−279) is composed of four domains: the catalytic
SET domain, located in the middle of this lobe, is surrounded by the zinc finger MYND,
insertion SET-I, and post-SET domains. Immediately C-terminal to the post-SET domain,
the polypeptide forms a large domain of about 150 residues that constitutes the C-
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Table 1. Crystallographic data and refinement statistics
Space group
Cell parameters (Å)
a
b
c
Wavelength (Å)
Resolution (Å)
Rmergea
Redundancy
Unique reflections
Completeness (%)
〈I/σ〉
Refinement
Resolution (Å)
Molecules/AU
Rworkc
Rfreed
RMSD
Bond lengths (Å)
Bond angels (°)
No. of atoms
Protein
Sinefungin/AdoHcy
Water
Zinc
B-factor (Å2)
Protein
Sinefungin/AdoHcy
Water
Ramachandran plot
Preferred regions (%)
Allowed regions (%)
Outliers (%)
a

Sinefungin
P212121

AdoHcy
P212121

57.5
75.1
112.5
0.97872
30.0-1.8
0.083 (0.503)b
6.0 (5.8)
45863
99.7 (99.5)
8.9 (2.8)

57.9
75.0
113.4
1.28215
30.0-2.03
0.102 (0.512)
11.3 (10.3)
32539
99.9 (99.1)
9.5 (4.6)

30-1.8
1
0.186 (0.224)
0.208 (0.275)

30-2.03
1
0.173 (0.193)
0.215 (0.226)

0.010
1.0

0.010
1.1

3465
27
429
3

3453
26
392
3

25.8
12.8
33.4

29.0
19.7
35.5

97.12
2.88
0.0

96.92
3.08
0.0

Rmerge=Σ|I-〈I〉|/ ΣI, where I is the observed intensity and 〈I〉 is the averaged
intensity of multiple observations of symmetry-related reflections.
b
Numbers in parentheses refer to the highest resolution shell.
c
Rwork= Σ|Fo-Fc|/ Σ|Fo|, where Fo is the observed structure factor, Fc is the
calculated struture factor.
d
Rfree was calculated using a subset (5%) of the reflection not used in the
refinement.
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terminal lobe (residues 280−432). This domain is conserved in the SMYD proteins and
was referred to as the CTD in our previous studies65. The CTD is composed of seven
antiparallel α-helices (αH−αN) rotated relative to one another by an approximately 25°.
This topology creates a right-handed superhelical structure generating a concave surface
on one side with a convex surface on the other. Despite the absence of any significant
sequence similarities, the overall fold of the CTD is reminiscent of that of TPR repeats
that adopt a helix-turn-helix structure. Given that the TPR repeats mediate specific
protein−protein interactions and the assembly of multiprotein complexes, the structural
similarity of the CTD and the TPR repeats suggests a function for the CTD as a proteinprotein interaction module.

The architecture of the catalytic SET domain of SMYD2 is essentially similar to
that of SMYD1 and SMYD365, 66, which features a “split” domain defined by two
separated segments, the S-sequence (residues 3–49) and the core SET domain (residues
183–246). Despite the split in the primary structure, the SET domain in SMYD2 has the
similar overall fold to other SET domain containing proteins, characterized by one central
310 helix (310-3) and 10 β-strands (β1−β5 and β8−β12) that are arranged into four
antiparallel β-sheets (Figure 3). Of particular importance are the loop connecting 310-3 and
β10 that contributes conserved catalytic residues and functions to bind the cofactor at the
bottom of the cofactor binding site, and the strand β8 and the loop following β10 that
form a narrow cleft predicted to accommodate substrate H3 peptide (Figure 4). However,
the SET domain alone is not sufficient for lysine methylation and it requires the
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Figure 3. Ribbon diagram of the SMYD2 structures. (A) Side view (left) and top view (right)
of the binary structure of SMYD2–sinefungin. (B) The structure of SMYD2–AdoHcy.
Secondary structures of SMYD2, α-helices, 310-helices, and β-strands are labeled and
numbered according to their position in the sequence. The S-sequence, MYND, SET-I, core
SET, post-SET, and CTD are depicted in light green, blue, pink, green, cyan, and red,
respectively, while sinefungin and AdoHcy are represented by balls-and-sticks and zinc ions
are denoted by purple spheres. (C) Superposition of two SMYD2 structures in complex with
sinefungin (red) and AdoHcy (cyan) based on their N-lobes. The maximum distance between
the equivalent regions in the outer edge of their C-lobes is indicated. The intradomain motion
is indicated by the straight arrow and the approximate rotation angle is given. (D) Ribbon
diagram of the structure of SMYD1 and (E) SMYD3 with the domains colored the same as
above.
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cooperation with three other domains, including the N- and C-terminal flanking domains
(pre-SET and post-SET) as well as the insertion SET-I domain72-74. The latter three
domains are not conserved with highly variable structures in the known SET proteins but
they occupy similar positions and play similar roles in these enzymes. Interestingly,
SMYD2 does not contain the pre-SET domain, though this domain is required by other
SET proteins to stabilize the SET domain fold or provide an extended histone binding
site73.

Both post-SET and SET-I domains are engaged in cofactor and substrate
binding72. The post-SET domain, which is immediately downstream of the SET domain,
is a small cysteine-rich region consisting of three short α-helices (αE, αF, and αG) that
are organized around a single zinc ion (Figure 3). The zinc ion is coordinated by four
highly conserved cysteine residues: Cys262, Cys264, and Cys267 from the post-SET
domain and Cys209 from the SET domain. This zinc ion thus appears to be important for
the folding of the post-SET domain and also tethers this domain to the SET domain. As a
result of this tethering, the post-SET domain lies close to the active site, with the loop
connecting αE and αF placed near the cofactor, and the C-terminal end of helix αE
positioned to participate in the formation of the substrate binding cleft. Similar to other
SMYD proteins65, 66, SMYD2 has a large SET-I domain consisting of a helix bundle (αB,
310-1, 310-2, αC, and αD) of as many as 84 residues, together with the MYND inserted
between the SET strands β5 and β8 (Figure 3). The equivalent region in Set7/9 or Dim-5,
however, contains only one or two small helices of 15–20 residues75, 76. In contrast to the
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MYND, the SET-I domain packs against the opposite face of the β-sheet containing β4,
β10, and β11, contributing to the cofactor and substrate binding. Specifically, the last two
helices (αC and αD) of the SET-I domain might be important for the recognition of the
H3 N-terminal residues (Figure 4), while the loop between the 310-1 and 310-2 helices
makes extensive contacts with the cofactor.

Figure 4. Cofactor binding pocket and substrate binding site.
(A) Interaction between SMYD2 and sinefungin. SMYD2 residues are represented by
balls-and-sticks with their carbon atoms colored according to the scheme in Figure 1.
Sinefungin is depicted by balls-and-sticks overlaid with 2Fo−Fc omit map calculated at
1.8 Å and contoured at 2.5 σ. Hydrogen bonds are illustrated as red broken lines. (B)
Ribbon diagram of the putative substrate binding site, illustrating the interaction
between SMYD2 and the modeled H3 peptide. The H3 peptide (1–10) from the Set7/9
structure (PDB code 1O9S) is displayed as balls-and-sticks with carbon atoms colored
yellow. (C) Superposition of the target lysine-access channels of SMYD2, SMYD1,
and SMYD3. The oval-shaped channel in SMYD2 is depicted by molecular surface.
Residues in SMYD2 are represented by balls-and-sticks, while residues in SMYD1 and
SMYD3 are displayed as sticks in purple and orange, respectively. Target lysine
(H3K4) is colored in yellow.

MYND mediates protein−protein interactions by binding to a proline-rich
sequence22. It has been demonstrated that the MYND present in SMYD2 interacts with
proteins containing the PXLXP motif, such as EBP41L3, a functional suppressor of
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epithelial ovarian cancers55. As shown in Figure 3A, the MYND domain consists of one
kinked α helix (αA) and two antiparallel β-strands (β6, β7) that are organized around 2
zinc ions. Although it forms direct contacts with the catalytic SET domain, the MYND
does not contribute residues to cofactor binding. In addition, this domain is more than 10
Å away from the putative substrate-binding pocket and may not be directly involved in
substrate recognition (Figure 4). These observations are in agreement with previous
findings that the MYND is dispensable for the histone methylation activity of SMYD255,
implicating that the MYND may primarily function as a protein−protein interaction
module and coordinate SMYD2 with other proteins to regulate tumor proliferation and
progression. The structure of the MYND of SMYD2 is very similar to that of SMYD1,
SMYD3 and AML1/ETO22, 65, 66, with the following pairwise RMSDs for Cα atoms over
40 residues: 0.48 Å, 0.53 Å, and 0.81 Å, respectively. Superposition of the MYNDs of
SMYD2 and AML1/ETO, which was solved in complex with a peptide containing the
“PPPLI” motif22, reveals that the proline-rich peptide is located in a shallow, fully
exposed surface groove that is readily accessible by other proteins. One side of the
groove is formed by a loop connecting β6 and β7, and the other side by the residues from
the N-terminal half of helix αA. Three highly conserved residues (Trp80, Gln76, and
Tyr70 in SMYD2), which are critical for AML1/ETO binding to the peptide are highly
superimposable in the two structures. The high structural similarity suggests a similar
mode of recognition of proline-rich sequences shared by these two MYNDs.

Active site characterized by a spacious target lysine access channel
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We have determined two structures of SMYD2 bound either to the cofactor
product AdoHcy or to a potent methyltransferase inhibitor sinefungin. The two structures
are remarkably similar to each other in terms of cofactor binding. Therefore, the
following discussion on the interaction between SMYD2 and the cofactor will be solely
focused on the SFG-bound SMYD2 structure. Similar to that in other SMYD proteins65,
66

, the L-shaped sinefungin binds in a deep surface pocket formed by the SET-I, SET and

post-SET domains (Fig 2A). In particular, the adenine moiety of sinefungin is
sandwiched between the benzyl ring of Phe260 and the aliphatic side chain of Lys17,
with its purine N6 and N7 atoms hydrogen-bonding to the backbone carbonyl and amide
groups of His207, respectively. The ribose hydroxyls of the cofactor make three
hydrogen bonds with the side chains of His137 and Glu135 and the carbonyl oxygen of
Tyr258. At the opposite end of sinefungin, the positively charged α-amino group is
recognized by a trigonal array of hydrogen bonds with the main chain carbonyl oxygens
of Lys17 and Arg19 and the amide Oδ of Asn206, while the carboxylate moiety forms
salt-bridge interactions with the guanidinium group of Arg19. The latter electrostatic
interactions are present in most SET proteins including SMYD1 but are replaced by a
hydrogen bond to a tyrosine residue in SMYD3, which represents an unusual variation66.
In the middle of sinefungin, the C−NH3 amine group, which is in place of the S–CH3
sulfonium of AdoMet, engages in two hydrogen bonds with the backbone oxygen of
Ala203 and the amide Oδ of Asn182. The similar interactions are expected in the case of
AdoMet, which might contribute to enzymatic function by destabilizing the active methyl
group. Collectively, the overall cofactor-binding mode of SMYD2 is structurally
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conserved with SMYD1 and SMYD3 and other SET enzymes and serves to orient the
methyl group of AdoMet into the methyltransfer pore during catalysis.

Although the SMYD2 structures were solved without substrate, superposition of
SMYD2 with histone H3-bound Set7/9, a H3 lysine 4 methyltransferase, offers insights
into substrate recognition. As shown in Figure 4B, the modeled H3 peptide binds in a
deep, rectangle-shaped cleft formed by the SET, post-SET and SET-I domains. In the
cleft, the β8 strand and the loop preceding the post-SET domain are predicted to interact
with substrate histone in a hybrid β-sheet-binding mode as shown in other SET
proteins72. Lys4 of the peptide is at the center of this β-sheet interaction with its side
chain inserted into the target lysine access channel that leads to sinefungin that binds on
the opposite face of the SET domain. Comparison of SMYD2, SMYD1, and SMYD3
reveals that the structures of the lysine access channel of these enzymes are similar to
each other with a large oval-shaped opening (Figure 4C). The residues in SMYD2
involved in the formation of the channel including Tyr240, Tyr258, Val202, Val215, and
Thr238, are highly structurally aligned with the equivalent residues in SMYD1 and
SMYD3, except for Phe184. The spacious lysine access channel is a characteristic feature
of SMYD proteins, which is mainly attributed to the replacement of some bulky aromatic
residues in Set7/9 or other SET proteins by small hydrophobic ones in SMYD proteins65,
66

. In SMYD1, substitution of Val214 by tyrosine, a mutation that would create a tighter

active site pocket, results in a significant increase in H3 binding and also enhances
SMYD1 methylation, indicating that this large channel made SMYD1 unable to
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effectively interact with the target lysine during methyl transfer, affecting its enzymatic
activity65.

A unique feature of SMYD proteins is the presence of the conserved CTD, which
is located near the substrate binding cleft and together with the SET domain forms a deep
canyon that spans the entire molecule65, 66. Similar to SMYD3, the putative substratebinding site of SMYD2 is located at the bottom of the 15-Å-deep crevice, with the CTD
acting like a lid and partially covering the active site pocket (Figure 3). However, because
of the location of the CTD, severe steric clashes are observed between the C-terminus of
the peptide and the CTD inner surface in the SMYD2−H3 model (Figure 4B). The steric
hindrance of the CTD suggests that the CTD prevents H3 binding and it may be required
to move away to allow substrate entry and efficient catalysis. Alternatively, this might be
an indication that the H3 peptide may adopt a different conformation when binding to
SMYD2. Considering the potential motion of the CTD, it is also likely that the CTD
conformation observed in the crystal structures represents a non-physiological state of the
protein. Importantly, mutation or deletion of the CTD significantly increased both
substrate binding and H3 methylation by SMYD1, demonstrating that this domain plays a
negative role in the regulation of the protein’s activity65. Together with previous
functional studies55,

65

, these observations support the idea that the histone

methyltransferase activity of SMYD proteins is regulated by autoinhibition that involves
the conserved CTD.
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Maintenance of SMYD2 autoinhibited conformation
SMYD2 methylates histone H3 to a very limited extent both in vitro and in vivo55,
and extensive interactions between the CTD and the SET domain appear to contribute to
the maintenance of the autoinhibited state of SMYD2 (Figure 5). Specifically, the
interactions involve contacts mediated by the turns connecting the CTD helices, which
form a contiguous ridge that is anchored to the concave face of the β-sheet containing β4,
β10, and β11. In addition, the residues within the antiparallel β-hairpin between β8 and
β9 appear to play a central role in the interaction with the CTD. This hairpin protrudes
deep into the middle of the concave face of the CTD, braced by the CTD helices and
forming numerous direct interactions with αH, αL, αM, and αN. In contrast, the
equivalent hairpin in SMYD1 interacts only with the last helix (αN) from the CTD,
separated by a large crevice from the other CTD helices. In particular, the aliphatic side
chain of Glu189 stacks with the aromatic ring of Tyr422, together with residues Leu191,
Leu379, Leu386, Met412, and Ile426 forming a continuous hydrophobic core that
stretches from the hairpin down to the bottom of the domain interface. Of particular
importance, however, are hydrogen bonds formed between with the guanidinium group
of Arg390, which projects from helix αL, and two acidic residues, Glu189 and Glu190 in
the β8–β9 hairpin. A similar interaction between the β8−β9 hairpin and the CTD was
also observed in SMYD3 but absent in SMYD1 that has an open conformation65, 66.
Given that the β8–β9 hairpin makes extensive contacts with the CTD, this hairpin is
likely to be important in holding the SET domain and the CTD together and maintaining
the closed conformation of the substrate-binding cleft.
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Figure 5. Stereo view ribbon diagram of the domain interface of N- and C-terminal lobes.
Residues are colored according to domain in which they reside, and hydrogen bonds are
indicated as red dashed lines.

Additional interactions that participate in stabilizing the closed conformation are
made among the residues in the loop preceding the post-SET domain and residues in the
third and fourth helices (αJ and αK) of the CTD (Figure 5). Specifically, Asp242 forms a
hydrogen-bond interaction with Tyr374, while Leu243 participates in a hydrophobic
cluster with Val337, Leu340, Tyr370, His373, and Tyr374 from the CTD. Most of these
residues are well conserved in SMYD family proteins65, suggesting that the interactions
between them may also contribute to the maintenance of the autoinhibited state.
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Interestingly, substitution of the corresponding Asp242 or Tyr370 by alanine is able to
destabilize the autoinhibited state of SMYD1, leading to a significant increase in both H3
binding and the enzymatic activity65.

Intradomain and interdomain flexibility of the conserved CTD
The intra- and interdomain bending of the CTD has been proposed to be central to
the release of the autoinhibitory effect exerted by the CTD66. However, there has been no
direct evidence to support this model. Significantly, the two SMYD2 structures in
complex with the cofactor analogs sinefungin and AdoHcy differ dramatically in the
conformation of the CTD (Figure 3C). Although the structures of SMYD2−SFG and
SMYD2−AdoHcy are highly superimposable with RMSD of 0.36 Å over 400 residues,
close examination reveals that the first two helices of the CTD (αH and αI) adopt
different conformations. These two helices bend outwards with the loop between the two
helices moving ~6 Å further away from the catalytic SET domain. This motion generates
a less closed conformation in the SFG-bound SMYD2 structure and slightly tightens the
cavity of the active site in SMYD2−AdoHcy. In agreement with the conformational
changes, the flexible nature of the αH and αI helices is also indicated by their higher than
average isotropic temperature factors of 41.9 Å2 for SMYD2−AdoHcy and 39.5 Å2 for
SMYD2−SFG (Table 1). We use the program DynDom to further analyze this domain
movement77. Two hinge bending motion regions are identified as containing residues
294−300 and 319−322, at which point the αH and αI helices pivot towards the SET
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Figure 6. Comparison of the crystal contacts of SMYD2−SFG and SMYD2−SAH.
SMYD2−SFG is depicted in red and its symmetry-related molecule in pink. Both
SMYD2−SAH molecules are colored gray. Residues involved in crystal contacts are
displayed as sticks and colored green and cyan in SMYD2−SFG and SMYD2−SAH,
respectively. The prime symbol denotes residues and secondary structures in the
symmetry-related molecules.
domain by the rotation. The hinge axis of the rotation runs approximately perpendicular
to the axis of the CTD superhelix, intersects the helix αH and is located 1.4 Å from Cα of
Arg299 and 1.3 Å from Cα of Asn300. The translation component of the screw operation
describing the domain movement is 1.5 Å so that the movement is essentially a pure
domain rotation. The crystal packing constraints appear to help to stabilize the
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conformational diversity of SMYD2. The overall crystal packing is effectively identical
in the SMYD2−AdoHcy and SMYD2−sinefungin complexes, except at the packing
interfaces that involve αH and αI (Figure 6). The different orientations of these two
helices are stabilized by the differences in crystal packing contacts that contain spatially
close but distinct sets of residues. Collectively, these findings provide the first evidence
of the intradomain flexibility of the CTD and the structural basis for the model of the
conformational changes in the CTD that regulates the activity.

The CTD is located over 30 Å distant from the cofactor and does not contribute
residues to cofactor binding. It is not apparent from the structure how such a long-range
conformational change is triggered by the cofactors and propagated from the cofactor
binding pocket, because of the highly superimposable cofactor binding sites and no
significant structural changes in their immediate neighboring regions. There are,
however, some differences caused by the CTD motion in the interaction networks
between the CTD and post-SET domain, including a new hydrogen bond between the
side chains of Arg299 and Glu248 and the potential salt-bridge interactions between
Arg306 and Asp256 in SMYD2−AdoHcy. Nevertheless, the long-range conformational
change triggered by the exchange of the cofactors could have at least one important
functional implication. Sinefungin more resembles AdoMet than AdoHcy in structure,
with the C–NH3 amine group in place of the S–CH3 sulfonium. Our findings may then
suggest that the binding of the substrate AdoMet to SMYD2 may partially relieve the
inhibition by the CTD by causing it to move away from the catalytic domain. The ability
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of the conformation changes induced by cofactors appears to be specific to SMYD2.
Several structures of SMYD3 have been recently been deposited in the protein data bank
including SMYD3−AdoMet, SMYD3−sinefungin, and SMYD3−AdoHcy complexes66, 78.
Despite marked differences in crystal packing, these SMYD3 complexes display
essentially identical structures independent of the types of cofactor, suggesting some
differences in allosteric properties among SMYD family members.

The exceptionally large differences in the domain-domain orientation or with
respect to the distance separating the N- and C-terminal lobes have been observed
between SMYD1 and SMYD365, 66. As a result of the differences, the CTD in SMYD3
adopts a closed conformation that blocks the putative H3K4 binding cleft, whereas the
SMYD1 CTD displays an open state with the active site completely exposed.
Interestingly, the SMYD2 structures display substantial differences from both SMYD1
and SMYD3 in regard to the CTD orientation. The differences can be viewed when the
N-terminal lobes from SMYD2, SMYD1, and SMYD3 are structurally aligned as shown
in Figure 3. In this view, the N-terminal lobe remains essentially unchanged, but the
CTDs move to either widen or narrow the deep crevice between the N- and C-terminal
lobes, essentially mimicking how a clamshell opens and closes. In particular, the Cα
atoms of some residues near the outer edge of the CTD move as much as 12 Å between
SMYD3 and SMYD1, whereas two SMYD2 structures appear to be a conformational
“intermediate” between the close form of SMYD3 and the open form of SMYD1.
Although the active site pocket of both SMYD2 and SMYD3 is partially closed by the

33

CTD that leads to steric clash with the modeled H3 peptide, significant differences are
observed in the first two helices of the CTD. The helices equivalent to αH and αI in
SMYD3 form direct contact with the linker region between the SET and MYND
domains66, but the SMYD2 structures reveal that these two helices swing outwards and
maintain a narrow gap with the SET domain on top of the active site pocket. This
structural difference, however, does not cause a significant change in the contact area
between the CTD and the rest of protein, with the total buried surface area in the domain
interface of 3766 Å2 in SMYD3 compared to 3796 Å2 and 3682 Å2 in SMYD2−AdoHcy
and SMYD2−SFG, respectively. Taken together, the differences in the domain–domain
orientation between SMYD2 and other SMYD proteins further suggest that the CTD is
able to undergo a hinge bending-like motion, which could regulate access to the active
site.

A model of SMYD2 activation by Hsp90
It has been reported that interaction between SMYD2 and Hsp90 is important for
the histone methyltransferase activity of SMYD2, which is in agreement with results for
SMYD1 and SMYD355-57. The manner in which Hsp90 contributes as a cofactor of
SMYD proteins is still unclear. Given the differences in the CTD conformations of
SMYD proteins, it has been proposed that Hsp90 activates SMYD proteins through the
displacement of the autoinhibitory effect of the CTD, which in turn leads to the exposure
of the CTD-blocked active site66. However, the question regarding the mechanics of how
Hsp90 causes the CTD motion remains elusive. Hsp90 is essential for maintaining the
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activity of numerous signaling proteins and it plays a key role in cellular signal
transduction networks79. In fulfilling its role, Hsp90 often operates by interacting with a
variety of proteins that contain a TPR domain. At the very C-terminal end of Hsp90 is the
TPR motif recognition site, a conserved MEEVD pentapeptide, that is responsible for the
interaction with many TRP proteins such as the immunophilins FKBP51/52, the stress
induced phosphoprotein Hop, cyclophilin Cyp40, and a protein phosphatase PP580.

Interestingly, a search using the Dali server reveals that the conserved CTD,
which sterically blocks the substrate binding site, resembles the structure of TPR
repeats81. The CTD is mainly comprised of three copies of 34-amino acid, helix-turnhelix TPR motifs, including αH−αI, αJ−αK, and αL−αM. As shown by superposition of
the CTD of SMYD2 and the TPR2 domain of Hop, the overall configuration of these two
domains are similar to each other with RMSD of 3.9 Å over 128 Cα atoms (Figure 7A).
The only significant difference is the first two helices of the CTD (αH and αI), which
have a different degree of superhelical twists. The structural similarity of the CTD and
TPR repeats leads us to hypothesize that the CTD might interact with Hsp90 via the Cterminal MEEVD pentapeptide of the chaperone, which may be important for SMYD2
activation. This hypothesis is in agreement with previous studies showing that Hsp90
interaction with SMYD2 was mediated through a region other than the MYND and SET
domains55. To assess potential interaction between the CTD and Hsp90, we performed a
modeling study using the structure of the TPR2 domain of Hop in complex with a Cterminal pentapeptide MEEVD of Hsp90 (Figure 7A). In the structure of the
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Figure 7. TPR-like CTD. (A) Superposition of the CTD of SMYD2−SFG (red) and the
TPR2 domain of Hop (sky blue) (PDB code 1ELR). The Hsp90 MEEVD peptide in
complex with the Hop TPR2 domain is displayed as balls-and-sticks with carbon atoms
colored yellow. (B) Model of the Hsp90 MEEVD peptide bound in the SMYD2 CTD.
The CTD is represented by molecular surface with color coding according to the
electrostatic potential: red, white, and blue correspond to negative, neutral, and positive
potential, respectively, whereas the peptide is shown as balls-and-sticks. Positively
charged residues predicted to be essential for peptide binding are labeled.
Hop−MEEVD complex, the Hsp90 peptide interacts with the Hop TPR2 domain in an
extended conformation, with the peptide sequence running parallel with the helices of the
TPR motifs82. The peptide-protein interactions are primarily dominated by hydrogen
bonds and salt-bridges involving the carboxylated groups of acidic residues and the Cterminus of the Hsp90 MEEVD motif interacting with conserved arginine and lysine
residues lining the basic peptide-binding channel of Hop. Despite the low sequence
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identities of 16% between the CTD and the TPR2 domain, most of the arginine, lysine
and asparagine residues responsible for Hop−Hsp90 interactions are structurally
conserved in SMYD2, including residues Arg306, Lys309, Gln345, Lys387, and Arg390.
By lining up along the concave surface of the CTD, these residues create a continuous
positively charged groove predicted for engagement of the Hsp90 acidic C-terminal
region (Figure 7B). This putative MEEVD binding site, however, is partially buried and
occupied by the loop between strands β8 and β9, the region that is involved in
maintaining the autoinhibited state of the protein by interacting with the CTD (Figure
7A). The structural similarity of the CTD to the TPR2 domain together with the buried
MEEVD binding site may suggest a mechanism of SMYD2 activation by Hsp90, which
may resemble how PP5 is activated by Hsp90. The crystal structure of autoinhibited PP5
reveals that the TPR domain of PP5 engages with the catalytic channel of the phosphatase
domain, restricting access to the catalytic site83. This autoinhibited conformation of PP5
is stabilized by the C-terminal helix that contacts a region of the Hsp90-binding groove
on the TPR domain. Hsp90 activates PP5 by disrupting TPR–phosphatase domain
interactions, permitting substrate access to the constitutively active phosphatase domain.
Based on these analyses, we propose a model of SMYD2 activation by Hsp90, in which
the Hsp90 MEEVD motif could compete with the β8−β9 hairpin for binding to the
SMYD2 CTD, displacing the CTD from the substrate binding site and causing a
conformational change in the CTD. This model is in agreement with the conformational
flexibility

of

the

CTD

as

revealed

by

the

structural

differences

between

SMYD2−AdoHcy and SMYD2−SFG (Figure 3). Additional research is required to
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support this proposed mechanism and to determine whether Hsp90 interacts with the
SMYD2 via the CTD and induces a conformational change in this domain.
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CHAPTER 3
Structural Insights into Estrogen Receptor Alpha Methylation by Histone
Methyltransferase SMYD2, a Cellular Event Implicated in Estrogen Signaling
Regulation

*Published in Journal of Molecular Biology 2014 Mar 1. pii: S00222836(14)00101-6. doi: 10.1016/j.jmb.2014.02.019. All authors agreed with including
their work in this dissertation.

Abstract
Estrogen receptor (ER) signaling plays a pivotal role in many developmental
processes and has been implicated in numerous diseases including cancers. We recently
showed that direct ERα methylation by the multi-specificity histone lysine
methyltransferase SMYD2 regulates estrogen signaling through repressing ERαdependent transactivation. However, the mechanism controlling the specificity of the
SMYD2-ERα interaction and the structural basis of SMYD2 substrate binding diversity
are unknown. Here we present the crystal structure of SMYD2 in complex with a target
lysine (Lys266)-containing ERα peptide. The structure reveals that ERα binds SMYD2
in a U-shaped conformation with the binding specificity determined mainly by residues
C-terminal to the target lysine. The structure also reveals numerous intrapeptide contacts
that ensure shape complementarity between the substrate and the active site of the
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enzyme, thereby likely serving as an additional structural determinant of substrate
specificity. In addition, comparison of the SMYD2-ERα and SMYD2-p53 structures
provides the first structural insight into the diverse nature of SMYD2 substrate
recognition and suggests that the broad specificity of SMYD2 is achieved by multiple
molecular mechanisms such as distinct peptide binding modes and the intrinsic dynamics
of peptide ligands. Strikingly, a novel potentially SMYD2-specific PEG binding site is
identified in the CTD domain, implicating possible functions in additional substrate
binding or protein-protein interactions. Our study thus provides the structural basis for
the SMYD2-mediated ERα methylation, and the resulting knowledge of SMYD2
substrate specificity and target-binding diversity could have important implications in
selective drug design against a wide range of ERα-related diseases.

Introduction
Estrogen signaling regulates numerous developmental processes and plays
important roles in cell growth and differentiation through influencing gene
transcription84. Abnormal function of this hormonal signaling pathway can lead to many
human diseases, including a variety of human cancers such as breast, ovarian, colorectal,
prostate, and endometrial cancers, and also other diseases such as endometriosis, fibroids,
osteoporosis, and cardiovascular disease44. Thus, detailed understanding of the molecular
mechanisms underlying estrogen signaling is of clinical and therapeutic importance. In
general, estrogen signaling is mediated by two estrogen receptors, ERα and ERβ, which
are ligand-activated transcription factors and belong to the nuclear receptor
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superfamily41. In the classical genomic pathway, the signaling mediated by these
receptors begins with binding of estrogen to the receptors ERα or ERβ, and then the
ligand-bound receptors dimerize and exert transcriptional control by binding to estrogen
response elements in their target genes41. Estrogen binding also induces a conformational
change in the receptors, which allows the recruitment of a number of coregulators,
including coactivators and corepressors, for specific regulation of gene activation and
repression41.

Epigenetic mechanisms are known to play key roles in the regulation of estrogen
signaling and contribute to ERα-mediated transcription85, 86. One such mechanism is
covalent histone modifications including methylation, acetylation, phosphorylation, and
ubiquitination on specific N-terminal residues of histones85. These modifications usually
work together to regulate the functioning of the genome by altering the local structural
dynamics of chromatin, primarily regulating its accessibility and compactness87. The
interplay of these modifications creates an epigenetic landscape that defines distinct
chromatin states compatible with either active or repressed gene transcription5. It was
shown that the estrogen-induced ERα transcriptional outcome is regulated by dynamic
interaction with various histone-modifying enzymes, which are generally associated with
ER coactivators and corepressors86. For instance, optimal ERα-mediated transcription
requires the recruitment of the coactivator complex p300/CBP, which acetylates local
histones and causes nucleosomal destabilization, consequently facilitating the binding of
transcription factors to promoter regions of estrogen responsive genes45. In addition, the
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recruitment of the mixed lineage leukemia histone methylases (MLLs) is required for
ERα transcriptional activity, and the knockdown of MLLs abolishes H3K4 trimethylation
resulting in significant suppression of the estrogen-induced HOXC13 activation46. These
findings, together with other epigenetic regulatory mechanisms85, demonstrate an
intricate relationship between epigenetics and estrogen signaling that function
cooperatively to specify ER transcriptional consequences.

Remarkably, some of the histone modifying enzymes are capable of regulating
estrogen signaling through direct ERα modification11, constituting another layer of
transcriptional regulation in signaling. For instance, the histone acetyltransferase p300
acetylates ERα at multiple lysine positions and regulates ERα transactivation in an
estrogen-dependent fashion88, 89. Acetylation of K266/268 by p300 has been shown to
promote ERα transactivation activity88, while K302/303 acetylation has been reported to
cause repression of ERα target gene expression89. Some of these residues are also subject
to methylation catalyzed by histone lysine methyltransferases including SET7 and
SMYD211, 51. Methylation of K302 by SET7 has been associated with increased ERα
activity and stability, and is essential for the efficient recruitment of ERα to its target
genes51. We recently showed that the histone H3K4/H3K36 methyltransferase SMYD2
regulates ERα transactivation by K266 methylation, which attenuates ERα chromatin
recruitment and prevents ERα target gene activation under an estrogen-depleted
condition11. This recent finding identified a previously undefined inhibitory methylation
event, contributing to a substantial body of evidence that posttranslational modifications
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of ERα provide complex and combinatorial regulation that assures the protein to be
tightly regulated and coordinating the appropriate transcriptional response. On the other
hand, our finding highlights the importance of elucidating the structural basis of the
SMYD2-mediated ERα methylation, as a necessary prerequisite of discovering small
molecules that could fine-tune ERα activity or stimulate the restoration of normal ERαdependent transcription programs.

In addition to ERα and histone H3, SMYD2 has been shown to be able to
methylate several other histone and nonhistone proteins90, which establishes SMYD2 as a
multifunctional protein playing important roles in diverse cellular processes. Initial
identification of SMYD2 as histone H3K4 and H3K36 methyltransferases suggests that
SMYD2 functions as an epigenetic regulator involved in transcriptional control of cell
proliferation and differentiation55, 91. Monomethylation of p53 by SMYD2 links SMYD2
to p53-mediated apoptosis and has been shown to contribute to tumorigenesis through
inhibition of p53 transcriptional activity38. In addition, recent evidence shows that
SMYD2-dependent RB methylation at K810 and K860 plays important roles in tumor
progression and growth, capable of regulating RB tumor-suppressing activity during cell
cycle progression and cellular differentiation in response to DNA damage35,
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. In

agreement with these observations, overexpression of SMYD2 has been associated with
multiple human malignancies, such as bladder cancer and esophageal carcinoma35-37,
indicating that it may act as a cancer-promoting protein regulating tumor progression via
the protein methylation activity. Furthermore, methylation of the heat shock protein
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Hsp90 by SMYD2 has been demonstrated as a key cytoplasmic event that stabilizes
myofilament organization by promoting complex formation between Hsp90, SMYD2,
and the sarcomeric protein titin32, 33. These findings together indicate that the diversity in
SMYD2 substrate specificity dictates the diversification of its biological function. On the
other hand, the complex picture of SMYD2-mediated methylation raises an intriguing
problem regarding how SMYD2 achieves broad substrate specificity, the nature of which
currently remains elusive.

Limited structural information on SMYD2-substrate complexes represents a
major obstacle in understanding the molecular basis by which SMYD2 recognizes a
diverse array of functionally different proteins. To date, the only available complex
structure is the structure of SMYD2 in complex with the p53 peptide92, 93. This is also the
only enzyme-substrate structure for the entire SMYD protein family2, 65, 66. Analysis of
this structure reveals the SMYD2-p53 interaction involves both the catalytic SET domain
and the tetratricopeptide repeat (TPR)-like CTD domain, suggesting the cooperative
action of these conserved domains may be important for specific p53 recognition92.
However, this structure alone offers little information on SMYD2 target binding
diversity, and the structural principles governing its complex-specific interactions still
remain unknown. Understanding the broad substrate specificity of enzymes generally
requires structural determination of the proteins bound with various ligands, and
comparative analysis of these liganded structures in turn will help to identify diversity
determinants responsible for their substrate discrimination94. In this study, we present a
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new SMYD2 structure in complex with a K266-containing ERα peptide. Comparison of
the SMYD2-ERα and SMYD2-p53 structures reveals that the SMYD2 targeting diversity
is facilitated by conformational flexibility in its substrate-binding pocket and also
depends on intrinsic ligand dynamics of different sequences. Strikingly, our structure
suggests the presence of an additional peptide-binding site that might confer an extended
substrate-binding mode or allows SMYD2 binding of two different proteins. This study
therefore provides important insights into the SMYD2-mediated ERα methylation and
could be valuable in the development of novel therapeutic strategies against many ERαdependent human diseases.

Materials and Methods
Protein Preparation
A DNA fragment encoding the full-length human SMYD2 was amplified by PCR
and cloned into the pSUMO vector (LifeSensors). Recombinant SMYD2, which contains
a N-terminal His6-SUMO tag, was then transformed into Escherichia coli BL21 Condon
Plus (DE3) cells for protein expression. The transformants were grown to an OD600
(optical density at 600 nm) of 0.4 at 37°C in 2 L LB medium, and then induced with 0.1
mM isopropylthio-β-D-galactoside at 15°C overnight. The cells were harvested by
centrifugation and lysed by French Press. The soluble fraction was then subjected to the
Ni2+ affinity chromatography purification followed by the cleavage of the His6-SUMO
tag with the yeast SUMO Protease Ulp1. SMYD2 proteins were separated from the
cleaved tag by a second Ni2+ affinity chromatography and further purified by the size
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exclusion chromatography. Finally, the proteins were concentrated to10−20 mg/ml in 20
mM Tris−HCl (pH 8.0), 150 mM NaCl, 1 mM β-mercaptoethanol, and 5% glycerol.

Crystallization and Data Collection
Crystallization was performed using the hanging drop vapor diffusion method at
20 °C. Initial SMYD2 crystals were grown by mixing 1 µl of a protein solution
containing 10 mg/ml SMYD2 and 2 mM AdoHcy with 1 µl of a well solution containing
15% PEG8000, 50 mM NaCl, and 100 mM Tris−HCl (pH 8.5). Crystals obtained under
this condition were crushed and then used as a seed stock for growing SMYD2-AdoHcyERα cocrystals. An 11-residue synthetic peptide (GGRMLKHKRQR) corresponding to
the ERα residues 261–271 (CPC Scientific) was used in cocrystallization. Prior to
cocrystallization, SMYD2 (3 mg/ml) was incubated with 2 mM AdoHcy and 2 mM ERα
peptide at 4 °C for 2 h. Complex crystals suitable for data collection were grown by
mixing 1 µl of the protein-ERα solution, 0.3 µl of the seed stock, and 0.7 µl of a well
solution containing 20% PEG 3350, 100 mM Tris−HCl (pH 8.7), and 5% ethanol.
Crystals typically appeared within 1 day and achieved their full size in a week. X-ray data
from single crystals were collected at beamline 21-ID-F at the Advanced Photon Source
(Argonne, IL) and were processed and scaled using the program XDS95. The crystals
belong to the tetragonal space group I4 and contain one molecule per asymmetric unit.

Structure Determination and Refinement
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The crystal structure of SMYD2 in complex with AdoHcy and ERα peptide was
solved by molecular replacement with the program PHASER96 using the mouse SMYD2sinfungin structure (PDB code: 3QWW) as a search model. Manual model building was
carried out in COOT69, and refinement was performed with PHENIX97. To reduce the
effects of model bias, iterative-build OMIT maps have been used during model building
and structure refinement. An elongated electron density clearly visible in the Fourier
difference map during the last refinement cycles was modeled using coordinates for
polyethylene glycol from the HIC-Up database98. The final model was analyzed and
validated with Molprobity99. All figures of 3D representations of the SMYD2-ERα
structure were made with PyMOL (www.pymol.org).

Protein Data Bank accession number
Coordinates and structure factors have been deposited in the Protein Data Bank
with accession number 4O6F.

Results and Discussion
Overall Structure of SMYD2-ERα Complex
The crystal structure of SMYD2 in complex with ERα peptide and cofactor
product AdoHcy has been determined at 2.82 Å by molecular replacement (Table 2). The
structure reveals that the overall fold of SMYD2 is bilobal with two lobes separated by a
deep cleft (Figure. 8A). The ERα peptide binds at the bottom of the cleft that connects to
the AdoHcy binding pocket located at the opposite face of the molecule (Figure. 8B).
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Table 2. Crystallographic data and refinement statistics
Data
Space group
Cell parameters (Å)
a=b
c
Wavelength (Å)
Resolution (Å)
Rmergeb
Rmeasc
CC1/2d
Redundancy
Unique reflections
Completeness (%)
〈I/σ〉
Refinement
Resolution (Å)
Molecules/AU
Rworke
Rfreef
RMSD
Bond lengths (Å)
Bond angels (°)
No. of atoms & B-factor (Å2)
Protein (3-432)
ERα Peptide (262-271)
N-terminal residues (262-265)
C-terminal residues (267-271)
PEG
AdoHcy
Water
Zinc
Nickel
a

I4
151.8
52.9
1.0781
75.9-2.82 (3.15-2.82)a
0.110 (0.446)
0.136 (0.553)
0.993 (0.813)
3.8 (3.6)
45284
83.6 (86.4)
10.8 (2.5)
75.9-2.82
1
0.176 (0.254)
0.237 (0.298)
0.006
1.49
3460; 29.8
90; 29.7
31; 45.1
50; 22.9
25; 27.2
26; 16.4
94; 21.5
3; 23.5
2; 72.4

Numbers in parentheses refer to the highest resolution shell.
Rmerge=Σ|I-〈I〉| / ΣI, where I is the observed intensity and 〈I〉 is the averaged intensity of multiple
observations of symmetry-related reflections.
c
Rmeas=Σ[(n/n-1)]1/2Σ|I-〈I〉| / ΣI, where n is the number of observations of a given reflection.
d
Half-dataset correlation coefficient.
e
Rwork= Σ|Fo-Fc| / Σ|Fo|, where Fo is the observed structure factor, Fc is the calculated structure factor.
f
Rfree was calculated using a subset (5%) of the reflection not used in the refinement.
b
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Similar to SMYD165, the N-lobe of SMYD2 (residues 3-276) is made up of four
domains: SET, SET-I, post-SET, and MYND; and the C-lobe formed by the CTD domain
(residues 280–425). The two lobes are connected by a nonconserved sequence (residues
277–279) of variable length, implicating a possible hinge motion between the CTD and

Figure 8. Overall structure of SMYD2-ERα complex. (A) Ribbon diagram of the
SMYD2-ERα structure, side view (left) and top view (right). The S-sequence, MYND,
SET-I, core SET, post-SET, and CTD are depicted in light green, blue, pink, green, cyan,
and red. Secondary structures, α-helices, 310-helices, and β-strands, are labeled and
numbered according to their position in the sequence. The ERα peptide, AdoHcy (SAH),
and polyethylene glycol (PEG) are displayed as sticks with their carbon atoms colored in
yellow, white, and light blue. Zinc ions are denoted by spheres and colored in purple. (B)
Surface representation of the SMYD2-ERα structure, side view (left) and top view
(right). SMYD2 is represented by the molecular surface colored according to domains.
The ERα peptide, AdoHcy, and PEG are represented in the same way as in Figure 8A.
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the rest of the protein2. Like other SMYD proteins65, 66, SMYD2 has a characteristic split
SET domain defined by two separate segments: the S-sequence (residues 3–49) and the
core SET domain (residues 183–245). The spatial association of these segments creates
an evolutionarily conserved fold comprised of one central 310 helix (310-3) and 10 βstrands (β1–β5 and β8–β12) that are arranged into 4 antiparallel β-sheets (Figure. 8). The
loop joining 310-3 and β10 contributes conserved catalytic residues and binds the cofactor
at the bottom of the cofactor-binding pocket (Figure. 9). The loop following β10 along
with the strand β8 participates in the formation of the substrate-binding cleft responsible
for accommodation of target ERα peptide (Figure. 10). Another functionally important
region is the loop between β8 and β9, which interacts with the ERα peptide and has been
shown to be required for SMYD2-mediated p53 methylation92.

The flanking post-SET domain and the insertion SET-I domain both associate
with the SET domain and assist the SET domain in lysine methylation73, 100, 101. The postSET, which is immediately downstream of the SET domain, is a small cysteine-rich
region comprised of 3 short α-helices (αE, αF, and αG) organized around a single zinc
ion (Figure. 8). The SET-I domain is a helix bundle (αB, 310-1, 310-2, αC, and αD) that is
inserted between the β5 and β8 strands of the SET domain (Figure. 8). Both domains
(post-SET and SET-I) participate in cofactor and substrate binding (Figure. 9 and 10).
The post-SET lies close to the active site, with the loop connecting αE and αF located
near the cofactor and with the C-terminal end of αE positioned to stabilize the SMYD2ERα interaction. For the SET-I domain, the functionally important structural elements are
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the helix αC that is important for the recognition of the ERα N-terminal residues and the
loop between 310-1 and 310-2 that makes extensive contacts with the cofactor. In contrast,
the MYND, which also associates with the SET domain, does not contribute residues to
cofactor and substrate binding. This observation is in agreement with previous findings
that the MYND is dispensable for the histone methylation activity of SMYD255. As
shown in Figure. 8, the MYND consists of one kinked α helix (αA) and two antiparallel
β-strands (β6 and β7) that are organized around two zinc ions. Evidence shows this
domain is responsible for the interaction between SMYD2 and EBP41L3, a PXLXP
motif-containing protein playing important roles in epithelial ovarian cancer
suppression55. It is therefore conceivable that the MYND may primarily function as a
protein-protein interaction module and coordinates SMYD2 with other proteins to
regulate tumor proliferation and progression2.

The exact function of the CTD domain in the SMYD protein family remains
controversial65, 92, 93. In SMYD1, the CTD has been shown to play a key role in protein
autoinhibition, and the deletion of the CTD increases the histone H3 binding and
methyltransferase activity65. In contrast, the CTD in SMYD2 has been demonstrated to
facilitate the formation of the substrate binding pocket and helps stabilizing p53
interaction92. It is not clear whether the functional differences of the CTDs may be related
to the structural differences observed between SMYD proteins. We previously showed
that there are exceptionally large differences in the domain-domain orientation between
SMYD proteins and with respect to the distance separating the N- and C-lobes2, 65, 66.
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SMYD2 appears to be a conformational intermediate between a closed form of SMYD3
and an open form of SMYD12. In addition, the CTD of SMYD2 has been demonstrated
capable of adopting two distinct conformations when different cofactor analogues bind2.
Nevertheless, the CTD itself is well conserved in the SMYD protein family comprised of
7 antiparallel α-helices (αH–αN) rotated relative to one another by approximately 25°
(Figure. 8). Such helix-turn-helix topology has been noted resembling the structure of
TPR repeats despite the absence of any significant sequence similarity2, 93. Given that the
TPR repeats mediate specific protein interactions and the assembly of multiprotein
complexes102, the structural similarity between the CTD and the TPR repeats suggests a
function for the CTD as a protein-protein interaction module.

Conserved Cofactor Binding Pocket
The L-shaped AdoHcy binds in a deep surface pocket formed by the SET, SET-I,
and post-SET domains (Figure. 9). The bottom of the pocket is made by the SET domain
signature motif NHXCXPN (residues 206–212), while the walls of the pocket are formed
by three loops that are triangularly arranged (β1–β2, 310-1–310-2, and αE–αF). In the
pocket, the adenine moiety of AdoHcy is sandwiched between the side chains of Phe260
and Lys17, with its purine N6 and N7 atoms hydrogen-bonding to the backbone carbonyl
and amide groups of His207. The ribose hydroxyls of AdoHcy make one hydrogen bond
with the Tyr258 carbonyl and another hydrogen bond to the His137 imidazole ring. At
the opposite end of AdoHcy, the carboxylate moiety is stabilized by salt-bridge
interaction with the Arg19 guanido group, while the positively charged α-amino group is
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Figure 9. Conserved cofactor binding
pocket. (A) Surface representation of
SMYD2 cofactor binding pocket. The
surface is colored according to SMYD2
domains. Bound AdoHcy is depicted by
sticks with the carbon atoms colored in
white. (B) Interaction between SMYD2
and AdoHcy. SmyD2 residues are
represented by sticks with the carbon
atoms colored according to the scheme in
Figure 1. AdoHcy is depicted by sticks
overlaid with 2Fo − Fc omit map
calculated at 2.82 Å and contoured at 1.5
σ. Hydrogen bonds are illustrated as red
dash lines.

recognized by triple hydrogen bonds with the carbonyls of Lys17 and Arg19 and the
amide Oδ of Asn206. The former electrostatic interaction is present in most SET proteins
including SMYD1 but is replaced by a hydrogen bond to a tyrosine residue in SMYD365,
66

, which represents an unusual variation. In the middle of AdoHcy, the Sδ atom is

surrounded by four oxygen atoms, of which two come from backbone carbonyls (Cys181
and Ala203), one from side chain hydroxyl (Tyr240), and one from side chain carbonyl
(Asn182). Some of these oxygens have been shown to make atomic contacts with the
AdoMet sulfonium and have been proposed to contribute to enzymatic function by
destabilizing the active methyl group65,

92

. Collectively, the overall cofactor-binding

mode of SMYD2 is structurally conserved with SMYD1 and SMYD3 and other SET
enzymes and serves to orient the methyl group of AdoMet into the methyltransfer pore
during catalysis.
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Specificity Determinants of SMYD2-ERα Interaction
The ERα peptide adopts a U-shaped structure and binds in the deep groove
formed by the N- and C-lobes (Figure. 10A). The base of the U-structure is sandwiched
between β8 and the loop preceding the post-SET domain, while the upward-protruding
U-arms make interactions with the CTD and SET-I domains from each side of the ERα
peptide (Figure. 10B). The stabilization of the SMYD2-ERα interaction is achieved by
networks of atomic interactions, which are mainly attributed to the residue at position 0
and the residues C-terminal to the target lysine (position 0 referring to Lys266). In
particular, the side chain of ERα Lys0 enters a deep hydrophobic channel composed of
invariant residues Tyr258 from αE, Phe184 from β8, and Tyr240 from the loop
connecting β10 and αE (Figure. 10C). These channel-forming residues are important for
SMYD2 function; for example, we have shown that mutation of Tyr240 to Phe greatly
diminishes ERα methylation in cells coexpressing ERα and the mutant, compared to the
cells coexpressing ERα and the WT SMYD211. In addition, the main chain of Lys0
makes one hydrogen bond to the Gly183 carbonyl group and two hydrogen bonds to the
highly conserved residue Thr185. As a result of these interactions, the Lys0 is fully
secured in the target lysine access channel with the side chain amine positioned 4.4 Å
away from the sulfur atom of AdoHcy (Figure. 10D). Similar distance has been observed
in many other SET methyltransferases and is deemed to be optimal for methyl transfer
between AdoMet and target lysine100.
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Figure 10. Interaction of SMYD2 and ERα. (A) Surface representation of SMYD2
substrate binding site. The surface is colored according to SMYD2 domains. The ERα
peptide is depicted by ribbon and colored in yellow. (B) Overall view of ERα binding.
SMYD2 is represented by ribbon and colored according to the scheme in Figure 1. ERα
residues are shown as balls-and-sticks overlaid with 2Fo − Fc omit map calculated at 2.82
Å and contoured at 1.5 σ. (C) Stereo view of the detailed interactions between SMYD2
and ERα. SMYD2 backbone and residues are represented by ribbon and sticks. ERα
residues are depicted by balls-and-sticks overlaid with translucent molecular surface.
Hydrogen bonds are illustrated as red broken lines. (D) Target lysine access channel
revealed by a slice section of the molecular surface. ERα and AdoHcy are represented by
balls-and-sticks with their carbon atoms colored in yellow and white.
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ERα recognition at the C-terminal side of the target lysine is mediated by
numerous hydrogen bonds and hydrophobic interactions. This is in sharp contrast to the
less significant N-terminal recognition (Figure. 10C). At +1 position, the interactions
with His+1 include a hydrogen bond from its backbone amide to the main chain of
Tyr240 and a hydrophobic contact between its imidazole ring and the side chain of
Ile241. At the substrate +2 position, the side chain of Lys+2 inserts in a deep
hydrophobic pocket, with the Nε atom hydrogen bonding to Val215 and the N atom
hydrogen bonding to the Glu187 side chain. Mutation of Glu187 to Lys has been shown
to significantly reduce the SMYD2-mediated p53 methylation92, underlining the general
importance of this residue in determining substrate binding specificity. Further Cterminal residues forming the ascending arm of the U-structure also contribute to specific
interaction (Figure. 10C). Residues at +3 and +4 positions are both involved in direct
contact with the CTD but to different substructures. The Nε atom of Arg+3 makes
hydrogen bond with Tyr344 from the helix αJ, whereas the side chain of Gln+4 makes
hydrogen bond with Arg306 located in αH. These observed interactions are consistent
with recent evidence that the CTD plays an important role in SMYD2 substrate
recognition, and the deletion of the CTD results in over 5-fold reduction in p53
methylation92. In addition, Arg+3 recognition involves the SET domain, and a hydrogen
bond is formed between the Nη1 atom of Arg+3 and the backbone carbonyl of Leu191. It
should be noted that the residue Leu191 and the aforementioned ERα-interacting residues
Gly183, Thr185, and Glu187 are all situated within the antiparallel β8–β9 hairpin,
delineating this hairpin as an important determinant of substrate specificity (Figure. 10B).
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Consistent with this notion, the β8–β9 hairpin is also responsible for Arg+5 recognition,
which involves bifurcated hydrogen bonding between the side chain of Arg+5 and the
side chains of His193 and Glu187. In contrast, there is no significant interaction with the
enzyme at the N-terminal side of the ERα peptide. This paucity of interaction is
consistent with its poorly defined N-terminal structure and the higher than average B
factors (Table 2). We observe no electron density for the first residue of the ERα peptide
and the weak density for the following two N-terminal residues (Gly-4 and Arg-3). The
specific interaction is observed only at position -1, where the side chain of Leu-1 is
recognized by hydrophobic contacts with Ser196 from the SET domain and Thr105,
Leu108, and Val179 from the SET-I domain. Together, our structural analysis indicates
that the specificity of the SMYD2-ERα interactions is mediated by the coplay of both
lobes, and the primary specificity-determining interactions appear to be C-terminal to the
target lysine.

In addition to the intermolecular contacts, the ERα peptide makes a number of
intrapeptide interactions that stabilize its U-shaped structure (Figure. 11). These
interactions include stacking contact of the His+1 imidazole ring with the Met-2 side
chain and the hydrogen bonding from the Nδ1 atom of His+1 to the O atom of Leu-1. In
addition, the side chain of Arg+5 adopts a U-arm parallel rotamer that allows the
formation of a hydrogen bond between its Nε atom and the main chain O of Arg+3.
These interactions create a folded substrate that has a small hydrophobic core formed by
the partially buried Met-2, His+1 and Arg+5 (Figure. 11A). Note that the overall
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backbone structure of the folded ERα peptide differs substantially from that observed in
other histone lysine methyltransferase-substrate complexes, where the bound peptide
usually adopts a linear stretched conformation100, 103, 104. In particular, the structure of the
ERα peptide is compactly asymmetric, having a horizontal cross section that is larger at
one end than the other (Figure. 11B). This structural asymmetricity appears to facilitate
substrate recognition by the funnel shaped-binding cleft between β8 and the β12–αE
loop, as the surface of the binding pocket is highly complementary to the shape of the
folded peptide (Figure. 11B). One would expect that the ordered ERα peptide structure
may contribute to SMYD2 substrate binding specificity and may encode specificitydetermining information additional to the peptide sequence. The structural order of
peptide has been shown to be an important determinant of substrate specificity in a few
other protein-peptide interaction systems. For example, experimental evidence shows that
the degree and rate of modification of arginine residues to citrulline residues by PAD
correlate not only with peptide sequence but also the structural order of the substrate105.
Antibodies raised against cyclic citrullinated peptides have been shown to result in a
more sensitive assay in RA diagnosis than one using linear citrullinated peptides,
indicating the local structure of the peptides has important biological functions that rely
on both sequence- and structure-dependent peptide recognition106. In addition, multiscale
theoretical simulation shows that the intrapeptide interactions determine the secondary
structure of amyloidogenic peptides and consequently the binding affinity to other
molecules107. Therefore, the observed ERα peptide structure and its ability to make
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intrapeptide contacts suggest an additional mechanism for determining SMYD2 substrate
specificity, representing another layer of complexity in SMYD2 substrate recognition.

Figure 11. ERα intrapeptide interactions. (A) Van der
representation of the folded ERα peptide. Hydrogen bonds
broken lines. (B) Shape complementarity between the ERα
substrate binding pocket. ERα is represented by molecular
SMYD2 is depicted by ribbon.

Waals (VDW) dot
are illustrated as red
peptide and SMYD2
surface (yellow) and

Mechanisms of SMYD2 Substrate Binding Diversity
To gain insights into SMYD2 substrate binding diversity, we compared the
SMYD2-ERα structure with the structure of SMYD2 in complex with p53 peptide
(Figure. 12). The two liganded SMYD2 structures are very similar with overall root
mean-square deviations of 0.6 Å for 430 Cα atoms. The main chains of the two peptide
ligands and the side chains of residues at positions -1, 0, +1, and +2 are superimposed
well, whereas large deviations are observed at the ascending arms of the U-structures that
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display completely different binding modes (Figure. 12A). In SMYD2-ERα, Arg+3 binds
in the β8–β9 region of the SET domain, whereas in SMYD2-p53 the side chain of Lys+3
is stabilized by interaction with Tyr370 and Tyr374 from the CTD and Asp242 from the
loop preceding the post-SET domain (Figure. 12B). Similarly, Arg+5 in SMYD2-ERα
interacts with the β8–β9 hairpin, whereas Gln+5 in SMYD2-p53 inserts its side chain
into a deep pocket formed by His341, Tyr344, Gln345, and Tyr370 from the CTD and
Leu244 and Tyr245 from the post-SET-preceding loop (Figure. 12C). It is not clear
whether the residues at position +4 also bind at different regions of the active site pocket,
because a glycine residue is found in p53 at this position (Figure. 12D). However, the
different backbone angles exhibited by Gln+4 and Gly+4 suggest any non-glycine residue
replacing Gly+4 would point its side chain to the SET domain contrasting with the CTDoriented conformation of the Gln+4 side chain. These findings indicate that SMYD2 has
multiple distinct binding sites that allow the accommodation of the U-arm residues with
different sequences, thereby explaining its broad specificity for these substrate positions
(Figure. 12H).

Notably,

the

structural

comparison

reveals

the

mechanisms

for

the

accommodation of diverse substrate residues at the U-base and the U-arms are different
(Figure. 12E). This difference appears to be related to the fact that SMYD2 has a wide Uarm binding site compared to a narrow U-base binding cleft that may not allow peptide
binding in different modes (Figure. 10A). Specifically, at the +1 position of the U-base,
the side chain of ERα His+1 follows a path similar to that of the aliphatic portion of the
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Figure 12. Structural comparison of SMYD2-ERα and SMYD2-p53. (A) Superposition
of the structures of the ERα peptide (yellow) and the p53 peptide (light blue; PDB code:
3TG5). (B), (C), (D), (E), and (F) Structural and binding differences of ERα and p53 at
position +3, +5, +4, +1, and -2. SMYD2 is colored according to domains while the ERα
and p53 peptides are shown in yellow and light blue. (G) Structural superposition of +3
peptide residues of SMYD2-ERα (yellow), SMYD2-p53 (light blue), and the second
SMYD2-p53 complex (gray; PDB code: 3S7D). A butanediol molecule (BU3) found in
the second SMYD2-p53 structure is depicted by sticks with the carbon atoms colored in
gray. (H) Sequence alignment of the target lysine and surrounding residues of SMYD2
methylation targets. Protein target names are shown at the left of the sequences. Target
lysine residues are shown as white on black, and similar residues appear shaded in cyan.
Position numbering is displayed above the alignment with position 0 referring to the
target lysine. Sequence numbering of the target lysine is displayed to the right of the
sequences.
p53 Ser+1 side chain, facing toward the SMYD2 residue Arg253. Note that the side chain
of this SMYD2 residue exhibits the large conformational changes in the two complexes.
In the SMYD2-p53 structure, the side chain of Arg23 is oriented toward the hydroxyl
group of Ser+1, whereas in the SMYD2-ERα complex, the guanidino group is rotated
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away from the bulkier side chain of His+1 because of steric effects (Figure. 12E). These
observations indicate that the conformational changes of Arg253 underlie the SMYD2
flexibility to accommodate ligands with +1 side chains of different size and suggest the
diversity in substrate recognition.

Comparison of the SMYD2-p53 structures solved by two independent groups92, 93
indicates that the intrinsic dynamics of the peptide ligand may facilitate diverse substrate
recognition by allowing considerably different peptide binding (Figure. 12F). In the two
SMYD2-p53 structures, the side chains of the p53 Lys+3 adopt two different
conformations. The second conformation is similar to the one observed for the ERα
Arg+3, whereas the binding site for the first conformation (see above) is occupied by a
butanediol molecule in the second SMYD2-p53 complex. This difference indicates that
the bound peptide has significant flexibility capable of assuming different conformations
in different solution environments. It also indicates that the intrinsic dynamics of the
peptide ligand allows for the interaction with different substrate recognition residues,
thereby likely contributing to the SMYD2 broad substrate specificity. It is of particular
interest to note the recognition of a peptide-loaded MHC molecule by the cognate T-cell
receptor depends on the dynamics properties of the peptides, and differential peptide
flexibility resulting from MHC polymorphisms can broaden and expand T-cell receptor
reactivity108.
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As discussed earlier, the intrapeptide interactions and the structural order of
peptide substrates may play a role in determining substrate specificity. Interestingly, the
structural comparison shows that the ERα and p53 peptides have completely different
intrapeptide interactions. Unlike the ERα peptide (Figure. 11), only one hydrogen bond
exists within the p53 peptide and there is no hydrophobic core present in the middle of
the U-structure (Figure. 12A). For the most part, these observed differences are due to the
conformational changes of the +2 residues in the two complexes. In SMYD2-p53, the
side chain of His+2 points away from the U-structure and is oriented toward the SET-I
domain. In SMYD2-ERα, the side chain of Met+2 is noted to participate in hydrophobic
contacts with the Arg+5 side chain and assists in the completion of the Arg+5 binding
pocket (Figure. 12G). Therefore, these ERα-specific interactions, together with the
different binding modes of +5 residues, underline the potential role of the intrapeptide
interactions in determining SMYD2 substrate binding diversity. Together, our
comparison of the SMYD2-ERα and SMYD2-p53 structures provides the first structural
information on how SMYD2 distinguishes and recognizes diverse substrates and suggests
that the broad specificity of SMYD2 is achieved by manifold molecular mechanisms
including multiple distinct binding sites, the conformational plasticity of the substratebinding pocket, the intrinsic dynamics of peptide ligands, and the substrate-specific
intrapeptide interactions. The interplay of these mechanisms would create sets of
complex-specific states that may underlie the SMYD2 ability to methylate a broad
spectrum of functionally and structurally different substrates.
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Figure 13. PEG binding site. (A) Surface representation of SMYD2 PEG binding site.
The surface is colored according to SMYD2 domains. PEG is depicted by sticks overlaid
with 2Fo − Fc omit map calculated at 2.82 Å and contoured at 1.5 σ. Nearby ERα
residues are displayed as sticks with the carbon atoms colored in yellow. (B) Putative
PEG interacting residues. SmyD2 residues are colored according to domains, ERα
residues are shown in yellow, and PEG (light blue) is represented in the same way as in
Figure 6A. (C) Structural superposition of the PEG binding site and the predicted Hsp90
binding site2. PEG is colored in light blue while the Hsp90 peptide (MEEVD) containing
the TPR binding motif is colored in green.

Unexpected PEG Binding Site
The most striking finding in the SMYD2-ERα structure is an extra long density
observed between the N- and C-lobes (Figure. 13). The entire stretch of this density is
close to the inner surface of the CTD, with the central portion of the density adjacent to
the ERα peptide-binding pocket. The density does not have a peptide characteristic
density feature and is not interpretable as ERα residues, AdoHcy, or water. Based on the
components in the crystal condition and the shape of the density, a polyethylene glycol
(PEG) molecule (n=8) was assigned into the density (Figure. 13A). The modeled PEG
molecule adopts an omega-turn conformation with one end anchored at a surface groove
formed by αH, αI, and αJ and the other end extending between the αJ and αK helices
(Figure. 13B). Residues likely contributing to PEG binding (within 4 Å of PEG) include
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Lys309, Tyr344, Gln345, Gly348, Leu351, Tyr352, Trp356, and Lys387 from the CTD
and Glu190 from the SET domain. The Arg+3 residue of the ERα peptide is in close
proximity to the PEG molecule, indicating that ERα may also participate in interaction
with PEG and stabilizes its position. It should be noted that all of the SMYD2 residues
listed above are not conserved across the SMYD protein family except Lys309. This
raises the interesting question whether the observed PEG binding in the present structure
is SMYD2 specific.

Bound PEG molecules have been reported in several other protein structures109111

. In most cases, the PEG binding has important functional implications and mimics the

ligand binding in the proteins, such as the putative odorant binding site of the odorant
binding protein AgamOBP1 and the cephalosporin binding site of the putative
methyltransferase CmcI112. While the functional significance of the PEG binding in
SMYD2 requires future investigation, several possibilities can be envisioned. First, the
PEG binding site might represent an additional substrate-binding pocket that could
participate in ligand binding leading to increased affinity or novel specificity. This
possibility is consistent with the observation that SMYD2 does not methylate the H3 or
H4 peptides efficiently but can act on the full-length histones 10-fold more effectively101.
Second, the PEG binding site might represent a protein interacting site responsible for
modulating SMYD2 cellular localization and transcription activities. Proteomic analysis
of the SMYD2 interactomes has shown that both CTD and MYND domains are
important protein-protein interaction domains interacting with proteins involved in cell
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cycle regulation and transcription regulation113. Third, the PEG binding site could play a
regulatory role and regulates SMYD2 methyltransferase activities by binding activator
proteins such as Hsp90. This suggestion is supported by the close proximity between the
ERα binding site and the PEG binding site, and also by the observed PEG binding site
overlapping with previously predicted Hsp90 binding pocket in the TPR-like CTD
domain (Figure. 13C)2. Therefore, our finding of the PEG binding site in the SMYD2
protein will potentially open many new research directions that could improve functional
understanding of this still poorly understood methyltransferase. On the other hand, the
structural details of the PEG binding site may be valuable in developing new methods
and strategies for selective drug design. For instance, strategies aiming at exploiting this
novel, potentially SMYD2-specific binding site may represent a promising approach for
the development of small molecules that could selectively inhibit this enzyme without
cross-reacting with a wide range of other functionally important methyltransferases. Such
strategy should have important implications in specific ERα signaling regulation and also
in many ERα-dependent human diseases.
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PART II
Structure Basis of Nherf1-Mediated CXCR2 Macromolecular Complex Assembly

CHAPTER 4
Structural Insights into Neutrophilic Migration Revealed by the Crystal Structure
of the Chemokine Receptor CXCR2 in Complex with the First PDZ Domain of
NHERF1
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Abstract
Neutrophils play an essential role in host defense against infection, but
uncontrolled neutrophilic infiltration can cause inflammation and severe epithelial
damage. We recently showed that CXCR2 formed a signaling complex with NHERF1
and PLC-β2, and that the formation of this complex was required for intracellular
calcium mobilization and neutrophilic transepithelial migration. To uncover the structural
basis of the complex formation, we report here the crystal structure of the NHERF1
PDZ1 domain in complex with the C-terminal sequence of CXCR2 at 1.16 Å resolution.
The structure reveals that the CXCR2 peptide binds to PDZ1 in an extended
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conformation with the last four residues making specific side chain interactions.
Remarkably, comparison of the structure to previously studied PDZ1 domains has
allowed the identification of PDZ1 ligand-specific interactions and the mechanisms that
govern PDZ1 target selection diversities. In addition, we show that CXCR2 can bind both
NHERF1 PDZ1 and PDZ2 in pulldown experiments, consistent with the observation that
the peptide binding pockets of these two PDZ domains are highly structurally conserved.
The results of this study therefore provide structural basis for the CXCR2-mediated
neutrophilic migration and could have important clinical applications in the prevention
and treatment of numerous neutrophil-dependent inflammatory disorders.

Introduction
Interleukin 8 receptor, beta (CXCR2) is a G-protein-coupled receptor that
mediates neutrophil migration to sites of inflammation and controls the positioning of
oligodendrocyte precursors in developing spinal cord by arresting their migration114, 115.
This receptor also functions in angiogenesis and wound healing, and plays an important
role in both spontaneous and inflammation-driven tumorigenesis114, 116, 117. In almost all
the cases, the ability of CXCR2 to direct cell trafficking and positioning depends on its
ability to bind to a repertoire of structurally and functionally related chemokines114. For
example, CXCR2 can bind all seven ELR-positive CXC chemokines, which include
growth-related protein (Gro)-α, -β, and -γ, epithelial-derived neutrophil attractant-78
(ENA-78), granulocyte chemotactic protein-2 (GCP-2), interleukin-8 (IL-8) and
neutrophil-activating peptide-2 (NAP-2)118. When binding to one of these chemokines,
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CXCR2 is capable of initiating G-protein heterotrimeric dissociation, which in turn
induces many downstream signaling events such as intracellular calcium mobilization
and actin polymerization both required for the chemokine gradient-directed cell
migration114.

Although the general process of the CXCR2-mediated signaling is well
established, the mechanisms regarding specific coupling of CXCR2 to its downstream
signaling molecules still remain poorly understood. We recently showed that CXCR2
formed a complex with its downstream effector PLC-β2 (phospholipaseC) via the
scaffold protein NHERF1 (Na+/H+ exchanger regulatory factor) in freshly isolated
neutrophils and bone marrow-derived neutrophils119. We also showed that this complex
played a critical role in the CXCR2-mediated signaling and was required for intracellular
calcium mobilization and neutrophilic transepithelial migration119. Furthermore, we
showed that the formation of this complex was mediated by the PDZ domains of
NHERF1, which bridged CXCR2 and PLC-β2 by binding to their C-terminal PDZbinding motifs119. Remarkably, the PDZ-mediated interaction of NHERF1 with the Cterminal sequence TSTTL of CXCR2 was essential for the functional assembly of the
CXCR2/NHERF1/PLC-β2 complex, and disrupting the interaction with a cell permeable
PDZ motif-containing peptide was sufficient to block the IL-8-induced CXCR2
neutrophilic

signaling119.

As

neutrophil

dysregulation

is

central

to

human

immunopathology120, the identification of this novel CXCR2 complex that contributed to
neutrophil chemotactic regulation suggested that targeting this trimeric complex inside
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the neutrophils might represent a new strategy for the treatment of numerous neutrophildependent inflammatory disorders119. This notion, in turn, highlights the importance of
elucidating the structural basis of the PDZ domain-mediated CXCR2-NHERF1
interaction, as a necessary prerequisite of discovering small molecules that could finetune CXCR2 activity or suppress excessive, disease-causing neutrophilic infiltration.

In general, PDZ domains mediate protein interactions by recognizing short amino
acid motifs at the C-termini of target proteins, through which PDZ domains play
important roles in signal complex assembling and receptor recycling as well as in
establishing cell polarity and directing protein trafficking121. Recent studies showed that
individual PDZ motifs are capable of recognizing up to seven C-terminal ligand residues,
with a vast potential to interact with a large number of biologically and functionally
diverse ligands122. However, in many cases, the specificity of the PDZ-peptide interaction
is determined mainly by the residues at positions 0 and -2 of the peptide (position 0
referring to the C-terminal residue), whereas other residues do not significantly contribute
to the interaction123. Based on that, PDZ domains have been grouped into two major
classes. Class I domains bind to peptides with the consensus sequence (S/T)X(V/I/L) (X
denoting any amino acid), while class II domains recognize the motif (F/Y)X(F/V/A)1,
124

. Corroborating this classification, structural studies revealed that PDZ domains share a

similar peptide recognition mode, with the 0 residue of peptide occupying a hydrophobic
pocket and the -2 residue participating in direct side chain interactions123, 124.
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In fact, the structural similarity in PDZ ligand recognition123, 124, together with the
fact that more than 500 PDZ domains in over 300 different proteins are present in the
human genome125, has led to years of intensive research regarding how PDZ domains, a
structurally simple protein interaction module, can achieve robust and efficient ligand
discrimination, the nature of which, however, still remains obscure. In this context, it is
interesting to note that PDZ binding is also enormously promiscuous, with one domain
capable of binding multiple targets126. For example, NHERF1 contains two PDZ domains
(PDZ1 and PDZ2) that are known to interact with a variety of transmembrane proteins,
such as the cystic fibrosis transmembrane conductance regulator (CFTR), the β2adrenergic receptor (β2AR), the platelet-derived growth factor receptor (PDGFR) and the
parathyroid hormone receptor (PTHR)127, 128. Moreover, PDZ promiscuity is exemplified
by the fact that some PDZ domains have the ability to bind peptide sequences that belong
to both class I and class II motifs129. Therefore, these examples have made it apparent
that detailed analysis and comparison of many proteins will be required to establish and
illuminate the full range of ligand discrimination operated by the PDZ domain fold130. A
high-resolution structural interpretation of individual PDZ domain function should in turn
provide considerable insights into the mechanisms regarding how the exquisite ligand
discrimination dictates the diversification of biological functions. For this reason, we
report here the high-resolution structure (1.1 Å) of the NHERF1 PDZ1 domain in
complex with the CXCR2 C-terminal peptide TSTTL. The structure reveals PDZ1
ligand-specific interactions and new mechanisms that govern the PDZ1 target selection
diversity. We also show that CXCR2 can bind both NHERF1 PDZ1 and PDZ2 in
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pulldown experiments, consistent with the observation that the two domains share highly
structurally-conserved peptide binding pockets. The results of this study therefore
provide important insights into the CXCR2-mediated neutrophilic migration and could be
valuable in the development of novel therapeutic strategies against many neutrophildependent inflammatory disorders.

Materials and Methods
Protein Expression and Purification.
For X-ray crystallography, a DNA fragment encoding the human NHERF PDZ1
(residues 11–94), and having the C-terminal extension TSTTL that corresponds to
residues 356–360 of human CXCR2, was amplified using PCR and cloned in the pSUMO
vector. The resulting clone that contains a N-terminal His6-SUMO tag was transformed
into Escherichia coli BL21 Condon Plus (DE3) cells for protein expression. The
transformants were grown to an OD600 (optical density at 600 nm) of 0.4 at 37 °C in LB
medium, and then induced with 0.1 mM isopropylthio-β-D-galactoside and grown an
additional 16 h at 15 °C. The cells were harvested by centrifugation and lysed by French
Press. The soluble fraction was then subjected to Ni2+ affinity chromatography
purification, followed by the cleavage of the His6-SUMO tag with yeast SUMO Protease
1. PDZ1 was separated from the cleaved tag by the second Ni2+ affinity chromatography
and further purified by size-exclusion chromatography. Finally, the protein was
concentrated to 10–20 mg/ml in a buffer containing 20 mM Tris–HCl (pH 8.0), 150 mM
NaCl, 1 mM β-mercaptoethanol

(BME), and 5% glycerol. For GST pulldown
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experiments, full-length NHERF1, NHERF1 PDZ1 (residues 11-94) or NHERF1 PDZ2
was cloned into the BamHI/XhoI sites of pGEX6P-1 plasmid, which was then
transformed into the Escherichia coli BL21 Gold (DE3) for protein expression. The
proteins were expressed essentially similar as described earlier and purified by affinity
chromatography using immobilized glutathione Sepharose 4B resin.

Crystallization, Data Collection and Structure Determination
Crystals were grown by the hanging-drop vapor-diffusion method by mixing the
protein (~8 mg/ml) with an equal volume of reservoir solution containing 100 mM
sodium acetate, pH 4.6, 2.7 M sodium chloride at 20 °C. Crystals typically appeared
overnight and continued to grow to full size in 3-4 days. Before X-ray diffraction data
collection, crystals were cryoprotected in a solution containing mother liquor and 25%
glycerol and flash frozen in liquid nitrogen. The data were collected at 100 K at beamline
21-ID-F at the Advanced Photon Source (Argonne, IL) and processed and scaled using
the program HKL200067. Crystals belong to space group P3121 with unit cell dimensions
a = b = 45.1 Å, c = 63.6 Å, and one molecule in the asymmetric unit. The structure was
solved by the molecular replacement method with program PHASER96 using the PDZ1CFTR structure (PDB code: 1I92) as a search model. The structure modeling was carried
out in COOT69, and refinement was performed with BUSTER70. The final models were
analyzed and validated with PROCHECK131. All figures of 3D representations of the
PDZ1-CXCR2 structures were made with PyMOL.

73

Protein Data Bank Accession Number
Coordinates and structure factors have been deposited in the Protein Data Bank
with accession number 4JL7.

Cell Culture and Transfection
HEK293 cells were obtained from the American Type Tissue Collection
(Manassas, VA) and maintained as described previously119. Briefly, the cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) supplemented
with 10% fetal bovine serum (FBS), 1% nonessential amino acids, 2 mM L-glutamine
and 25 mg/mL penicillin or streptomycin. The cells were maintained at 37 °C in a 5%
CO2-95% air atmosphere and routinely passaged at a ratio of 1:4 when 70-80% confluent.
Transfection was carried out with the Lipofectamine 2000 (Invitrogen) transfection kit
according to the manufacturer’s protocol. HEK293 cells were plated in 75-cm2 flasks.
After reaching of 80%–90% confluency, cells were provided with 12 ml of fresh medium
and transfection was performed with pTriEx-4 vector encoding HA-tagged human
CXCR2, murine CXCR2, and FLAG-tagged CXCR2 C-tail fragments.

Pulldown Assays
GST pulldown assay were preformed essentially similar as described in our
previous studies119. Briefly, HEK293 cells overexpressing CXCR2 proteins were lysed
with cell lysis buffer (PBS, 0.2% Triton X-100) supplemented with a mixture of protease
inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 g/ml of aprotinin, 1 g/ml of leupeptin,
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and 1g/ml of pepstatin) and phosphatase inhibitor mixture (Sigma). The cell lysates were
cleared by centrifugation at 16,000 g for 10 min, and then incubated with GST-NHERF1
fusion constructs (GST-NHERF1, GST-PDZ1, GST-PDZ2) or GST alone for 3 h at 4 ºC.
After incubation, the complex was mixed with glutathione-agarose beads (BD
Biosciences) and incubated for 1 h at 4 ºC with general shaking. The beads were then
washed three times with 1 ml of lysis buffer, pelleted at 500g for 30 s, and boiled in
Laemmli sample buffer. Finally, HA-tagged CXCR2 proteins, which bound to GSTNHERF1 proteins, were resolved by SDS-PAGE and detected by anti-HA antibodies. To
verify direct CXCR2/NHERF1 interaction, purified GST-NHERF1 PDZ domains (0.5
uM; GST-NHERF1 PDZ1, GST-NHERF1 PDZ2, GST-NHERF1 PDZ1+2) or GST alone
were mixed with a synthetic CXCR2 C-tail peptide (1.0 uM; last 13 a.a. with a biotinconjugate at N-terminus) in binding buffer (PBS + 0.2% Triton X-100 + protease
inhibitors) at 22-24ºC for 1 hr. The mixtures were incubated with Streptavidin beads (for
binding to biotin-conjugate in the peptide) for 2 hrs. The beads were washed three times
with binding buffer, and eluted with Laemmli sample buffer containing βmercaptoethonal. The eluents were resolved by SDS-PAGE, and immunoblotted with
anti-GST IgG.

Results and Discussion
Structure Determination
To facilitate NHERF1-CXCR2 cocrystallization and reveal the mechanism by
which NHERF1 recognizes CXCR2, we generated a chimeric protein with the C-
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terminus of the NHERF1 PDZ1 domain (residues 11–94) fused to five amino acids
(TSTTL) corresponding to the CXCR2 residues 356–360. We reasoned that such design
would take advantage of functional interaction between CXCR2 and NHERF1, allowing
efficient crystal packing by promoting intermolecular contacts in a more site-specific
manner. This strategy has previously been applied to several PDZ-target complexes1, 4,
132

, and indeed proved to be effective in obtaining diffraction-quality PDZ1-CXCR2

crystals in this study. The crystals diffracted to high resolution (1.1 Å), and the structure
was determined by molecular replacement. The model was refined to Rwork of 18.7% and
Rfree of 21.7%, and the evaluation of its stereochemistry using PROCHECK showed that
89.2% of the residues are in the most favored, 8.1% in the additional allowed, and 2.7%
in the generously allowed regions; no residues are found in the disallowed regions (Table
3).

Overview of the Structure
The crystal structure reveals a polymeric PDZ1 arrangement with the carboxyl
terminal region TSTTL of one PDZ1 molecule bound to a neighboring PDZ1, which
leads to the formation of a linear, infinite PDZ1 filament throughout the crystals. The
overall topology of NHERF1 PDZ1 is similar to other PDZ domains124, consisting of a
six-stranded β-barrel (β1–β6) that is capped top and bottom by two α-helices (αA and
αB) (Figure. 14A). The β-barrel has a hydrophobic interior, lined up with highly
conserved residues, including Leu59, Ile39, Phe26, Cys15, Val86, Leu88, Leu59, and
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Table 3. Crystallographic data and refinement statistics
Space group
Cell parameters (Å)
a=b
c
Wavelength (Å)
Resolution (Å)
Rmergea
Redundancy
Unique reflections
Completeness (%)
〈I/σ〉
Refinement
Resolution (Å)
Molecules/AU
Rworkc
Rfreed
RMSD
Bond lengths (Å)
Bond angels (°)
No. of atoms
Protein
Peptide
Water
Chloride
B-factor (Å2)
Protein
Peptide
Water
Chloride
a

P3121
50.4
66.0
0.97872
20.0-1.16 (1.20-1.16)
0.063 (0.463)b
9.7 (7.0)
33912
100 (100)
19.1 (3.3)
20.0-1.16
1
0.186 (0.217)
0.208 (0.248)
0.011
1.2
655
36
102
3
20.4
15.1
27.8
16.4

Rmerge=Σ|I-〈I〉|/ ΣI, where I is the observed intensity and 〈I〉 is the averaged intensity
of multiple observations of symmetry-related reflections.
b
Numbers in parentheses refer to the highest resolution shell.
c
Rwork= Σ|Fo-Fc|/ Σ|Fo|, where Fo is the observed structure factor, Fc is the calculated
struture factor.
d
Rfree was calculated using a subset (5%) of the reflection not used in the refinement.
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Val90 (Figure. 14B). These residues are also evolutionally conserved across other PDZ
motifs, suggesting their universal role in stabilizing PDZ fold by forming a continuous
hydrophobic core123. In contrast, the outside of the barrel is rather hydrophilic, with a
region enriched with basic residues predicted to be involved in membrane association and
direct interaction with acidic lipids133. These putative lipid-binding residues include
Lys32, Lys34 and Arg40, which are located within β3 and its preceding loop with their
side chains facing toward the solvent (Figure. 14A). The interaction of cholesterol with
these surface residues was required for dynamic NHERF1-CFTR colocalization, and
disruption of the NHERF1’s cholesterol-binding activity resulted in aberrant CFTR
channel activation133.
In addition to its amphipathic nature, the PDZ1 β-barrel is structurally
asymmetric, having a circular cross section that is larger at one end than the other
(Figure. 14A). At the smaller end, the PDZ1 N- and C-termini curl close together and
block the barrel opening. On the opposite end, a helix (αB) is positioned in a manner that
still permits access to the barrel’s interior core region. This helix (αB) is stabilized by
VDW contacts with the residues from β3 and β4 but stays ~9 Å apart from β2. The nearly
parallel arrangement of αB and β2 creates a shallow surface groove approximately 18 Å
long, 8 Å wide, and 4 Å deep. The groove stretches deeply into the central cavity of the
β-barrel, forming a peptide-binding pocket that is responsible for highly robust protein
interactions122. Similar to other PDZ structures1, 4, the CXCR2 C-terminal peptide TSTTL
inserts into the PDZ1 binding pocket as an additional β-strand antiparallel to β2 (Figure.
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Figure 14. Structure of NHERF1 PDZ1 in complex with the CXCR2 C-terminal sequence
TSTTL. (A) Ribbon diagram of the PDZ1-CXCR2 structure, front view on the left and
side view on the right. PDZ1 is shown in purple and the CXCR2 peptide shown in green.
Secondary structures of PDZ1, α-helices and β-strands, are labeled and numbered
according to their position in the sequence. Side chains of putative PDZ1 lipid-binding
residues are depicted by balls-and-sticks in the side view of the structure. (B) Sequence
alignment of selected PDZ domains. The alignment was performed by ClustalW42,
including human NHERF1, human NHERF2 and mouse PDZK1. Identical residues are
shown as white on black, and similar residues appear shaded in cyan. Secondary structure
elements are displayed above the sequences and labeled according to the scheme in Fig.
14A. Sequence numbering is displayed to the left of the sequences, with every 10th
residue marked by a dot shown above the alignment. (C) Sequence alignment of the last
five residues of natural NHERF binding targets. The alignment includes CXCR2, CFTR,
β2AR, PDGFR, PTHR, Npt2a (type 2 sodium-phosphate cotransporter), purinergic
receptor P2Y1, CCR5 (C-C chemokine receptor type 5), and AQP9 (aquaporin 9).
Protein names are shown at the left of the sequences. Position numbering is displayed
above the alignment, with position 0 referring to the very C-terminal residue.
15). In this setting, the invading peptide is highly ordered as indicated by high quality
electron density maps (Figure. 15A) and below average B factors (Table 3). It should be
noted that the CXCR2-binding pocket is topologically distinct from the putative lipid
binding sites (Figure. 14B), and that mutation of the cholesterol-binding residues did not

79

lead to significant changes in the NHERF1 ligand-binding activity133. Although the role
of cholesterol in CXCR2 signaling is currently unknown, the PDZ topological asymmetry
that places the CXCR2-binding sites opposite to the domain termini, along with direct
cholesterol-NHERF interaction being important for cell signaling and protein
networking133, suggests a signaling platform with PDZ1 serving as a dual-specificity
scaffold to bring together the membrane and juxtamembrane signaling complexes133.

Figure 15. Interactions between PDZ1 and CXCR2. (A) Stereo view of the PDZ1 ligandbinding site bound to the CXCR2 C-terminal peptide. PDZ1 residues are represented by
balls-and-sticks with their carbon atoms colored in purple. CXCR2 peptide is depicted by
balls-and-sticks overlaid with 2Fo − Fc omit map calculated at 1.16 Å and contoured at
1.8 σ. Hydrogen bonds are illustrated as red broken lines. (B) Surface representation of
the PDZ1 binding pocket with coloring according to the electrostatic potential: red,
white, and blue correspond to negative, neutral and positive potential, respectively. The
CXCR2 peptide is depicted by balls-and-sticks overlaid by its transparent molecular
surface.
Specificity Determinants of Consensus PDZ1 Binding Motif
The CXCR2 pentapeptide (TSTTL) binds PDZ1 in an extended conformation,
forming numerous contacts with β2 and αB and burying a total solvent-accessible surface
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area of 360 Å2 (Figure. 15). Only the last four residues of CXCR2 make specific contacts
to PDZ1, whereas the first threonine adopts a well-defined conformation but is not
directly involved in PDZ1 recognition, indicating that it does not contribute to the
specificity of the interaction. Similar to other PDZ domains123, the specificity and affinity
of the PDZ1-CXCR2 interaction are achieved mainly by the residues at positions 0 and -2
of the peptide (position 0 referring to the very C-terminal residue), whereas residues -1
and -3 appear to be important for ligand-specific interactions (see below). Specifically,
the side chain of CXCR2 Leu0 enters a deep hydrophobic pocket composed of invariant
residues Tyr24, Phe26, and Leu28 from β2, and Val76 and Ile79 from αB. These pocketforming residues are important for NHERF1 functions; for example, mutation of Tyr24
and Phe26 completely abolished the NHERF1-targets interaction and significantly altered
cellular processes essential to tumor metastatic behaviors134.

In the PDZ1 pocket, the position of Leu0 is fully secured by a hydrogen bond
from its carbonyl oxygen to the Tyr24 amide nitrogen and by triple hydrogen bonding to
the PDZ1 carboxylate-binding motif (Figure. 15A). The carboxylate-binding motif,
located between β1 and β2, has a left-handed helical conformation that results in three
amide nitrogens being directed toward the peptide, thereby allowing the hydrogen-bond
formation between the Leu0 carboxylate and the amides of Phe24, Gly25, and Phe26. In
addition, Leu0 fits tightly in the PDZ1 pocket, with the side chain directly abutting the
benzene ring of Phe26 and the isobutyl group of Ile79. Remarkably, the surface of the
pocket is highly complementary to the shape of leucine (Figure. 15B), which thus
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provides a structural basis that governs the high affinity binding between CXCR2 and
NHERF1119. This stereochemical complementarity also suggests that any model that
substitutes Leu0 to larger hydrophobic residues would generate substantial steric clashes;
to smaller ones would be energetically unfavorable. Interestingly, recent molecular
dynamic simulation studies showed that replacement of Leu0 by Val or Ala of the CFTR
ligand resulted in fewer interactions with NHERF1 PDZ1 and substantially lower binding
energy135. Collectively, the present structure demonstrates, for the first time, the PDZ1
binding selectivity for the CXCR2 C-terminal leucine, which is mediated by the
stereochemically complementary hydrophobic interaction in a fashion that is highly
conserved in class I PDZ motif123. This conserved binding selectivity in turn provides
structural rationalization for the importance of Leu0 in CXCR2 function. The competition
experiments using the leucine-mutated peptides did not affect IL-8-induced CXCR2
signaling, but the treatment of bone marrow neutrophils with a CXCR2 peptide
containing an intact PDZ motif, disrupting NHERF1-CXCR2 complex, resulted in a
significant

inhibition

of

intracellular

calcium

mobilization,

chemotaxis,

and

transepithelial migration of neutrophils119.

Another conserved feature of the PDZ1-CXCR2 interaction is that Thr-2 engages
in numerous specific contacts with PDZ1 and plays an important role in determining the
specificity and affinity of the interaction. Specifically, the amide nitrogen of Thr-2
hydrogen bonds to the carbonyl oxygen of Leu28, while the backbone carbonyl of Thr-2
hydrogen bonds to the main chain amide of the same residue. In addition, the side chain
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hydroxyl of Thr-2 hydrogen bonds with the imidazole ring of His72, with its side chain
aliphatic carbon making direct hydrophobic contacts to the conserved Val76. These
observed interactions are consistent with biochemical studies showing that direct contacts
between ligand -2 residue and the residues from PDZ αB helix are critical for the binding
specificity of class I PDZ-ligand interaction122, 123. For example, mutation of the His72equivalent residue in ERBB2IP-1 to Tyr, Asn, Gln or Lys, all capable of forming
hydrogen bonds to threonine, did not alter specificity significantly, whereas substitution
of the residue with Leu, Val or Met resulted in class II specificity profiles with preference
for hydrophobic residues at -2 position122. Therefore, our structure, coupled with these
previous results, indicates that the stabilization and specificity of PDZ1-CXCR2
interaction are dependent on both Leu0 and Thr-2 that possess the ability to form
networks of hydrogen bonds and hydrophobic interactions with NHERF1.

Ligand-specific PDZ1-CXCR2 interactions
Compared to the motif residues (0 and -2), the peptide residues at positions -1 and
-3 are largely exposed, with both side chains oriented upwards in the PDZ1-CXCR2
complex (Figure. 15). As a result of this orientation, the -1 and -3 residues make fewer
direct contacts with PDZ1 and bury a much less extent of solvent-accessible surface areas
than the motif residues (50 Å2, -1; 40 Å2, -3; 80 Å2, -0; 75 Å2, -2). These findings are
consistent with previous evidence that both -1 and -3 residues in the peptide ligands were
less stringently specified by individual PDZ domains than the residues at the 0 and -2
positions123. Specifically, the interactions with Thr-1 include a direct polar contact from
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its side chain hydroxyl to the side chain of His27 and a water-mediated hydrogen bond
between its carbonyl oxygen and the side chain of Arg80 (Figure. 15A). In these aspects,
the PDZ1-CXCR2 structure differs significantly from the structures of other PDZ1-ligand
complexes. In PDZ1-CFTR, the guanido group of Arg-1 forms two salt bridges to the
Glu43 side chain and two hydrogen bonds with the carbonyl oxygen of Asn221, while in
PDZ1-β2AR and PDZ1-PDGFR, the nonpolar residues at position -1 of the peptide
ligands engage in direct hydrophobic interactions with the imidazole ring of His274.
These observed differences reveal that there is considerable diversity in PDZ1 interaction
with -1 residue of different ligands, manifested by four chemically different amino acids
(Asn22, His27, Glu43, and Arg80) combined in the discrete ways to discriminate the
ligand residues of different hydrophobicity and polarity. This diversity reflects a high
degree of selectivity in NHERF1 ligand recognition, consistent with a vast potential for
PDZ domain family to bind different sequences122.

The interactions between PDZ1 and CXCR2 at position -3 of the peptide are also
very different compared to other PDZ1 complexes. In PDZ1-CXCR2, the hydroxyl group
of Ser-3 forms a direct hydrogen bond with the His29 side chain and a water-mediated
hydrogen bond to the imidazole ring of His27 (Figure. 15A). In contrast, the side chain of
residue Asp-3, which is common in CFTR, β2AR, and PDGFR, is engaged in salt bridge
interaction with the Arg40 guanidinium and direct hydrogen bonding to the side chain of
His274,

124

. These structural differences appear to be important for PDZ1 ligand

discrimination, as it was shown that highly specific contacts with different types of
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contextual residues contributed significantly to the binding specificities of all peptidemediated protein interactions136. In agreement with this conclusion, the structure of the
NHERF2 PDZ2 in complex with the PSTRL sequence revealed the occurrence of similar
interactions

between

Ser-3

and

a

histidine

residue

(His166)

of

the

PDZ

domain132.Remarkably, the NHERF2 PDZ2 His166 residue corresponds to NHERF1
PDZ1 His29 (Figure. 14A), suggesting that the amino acid at this position may play a
critical role in specific ligand recognition via interaction with the -3 residue of the
peptide. Taken together, the present structure indicates that the peptide residues at
positions -1 and -3 contribute to ligand specific PDZ1-CXCR2 interactions, suggesting
that these positions may have been naturally selected to facilitate PDZ ligand selection
within a complex network of NHERF-scaffolded interactions122. Interestingly, the
residues at the -1 and -3 positions exhibit significant variability across natural NHERF1
binding targets, with the two-residue combination unique to each characterized ligand
(Figure. 14C).

The considerable contacts between PDZ1 and the residues at positions -1 and 3
suggest that these residues may play an important role in the affinity of the PDZ1CXCR2 interaction. Consistent with this suggestion, affinity selection experiments
showed that NHERF PDZ1 almost exclusively selected ligands with arginine at position 1 from random peptides, and mutation of Arg to Ala, Phe, Leu, or Glu decreased the
affinity of the PDZ1-ligand interaction by 2-10 fold1, 137. In addition, it has been shown
that position -3 is also an important determinant of binding affinity, with PSD-95
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preferring to bind peptides with acidic side chains at this position123. Furthermore,
analysis of the binding specificities for nearly half of over 330 PDZ domains in human
and worm revealed that there was a strong correlation between natural PDZ sequences
and ligand specificities at both -1 and -3 positions of peptides122. Remarkably, the PDZ
binding preferences at these positions can be influenced by multiple structural and
chemical mechanisms involving both direct contacts and cooperative, long-range effects,
suggesting that binding specificities can evolve rapidly, thus enabling PDZ for robust
differentiation between biologically diverse ligands122. Therefore, our structure, together
with these previous findings, suggests that the ligand specific contacts between PDZ1 and
the CXCR2 -1 and -3 residues are important for the binding affinity and specificity of the
PDZ1-CXCR2 interaction. In a broad term, the ligand specific interactions at these
positions could lead to different PDZ-ligand complex stabilities, which, in conjunctions
with an increasingly complex NHERF interaction network138, may determine signaling
orchestration and underlie the highly coordinated regulation of manifold NHERFcontrolled signaling events139. In support of this idea, recent biochemical studies
suggested that NHERF1, NHERF2, and CAL competed to regulate CFTR endocytic
processing, and the differences in their CFTR binding affinities were required for CFTR
to efficiently escape CAL-mediated degradation through repeated rounds of uptake and
recycling127.

Structural Comparison Reveals PDZ1 Target Selection Specificity
To uncover the structural details that govern the CXCR2-NHERF1 ligand specific
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interactions, we compared the PDZ1-CXCR2 structure to the crystal structures of all
available NHERF1 PDZ1-ligand complexes, including PDZ1-CFTR, PDZ1-β2AR, and
PDZ1-PDGFR1, 4. The structural comparison reveals that the four PDZ1 structures are
highly similar, with pairwise RMSDs (root-mean-square differences) for entire Cα atoms
ranging from 0.48 to 0.83 Å (Figure. 16A). Larger differences in the PDZ1 backbone are
found at two loop regions (β2-β3 and α2-β6 loops), but note that these loops made of
non-conserved residues (Figure. 14B) are conformationally flexible, as indicated by
poorly defined electron density and higher than average B factors (data not shown).
Moreover, the backbone conformations of the bound peptides are also highly
superimposed (RMSDs from 0.48 to 0.83 Å), as are their relative spatial positions to the
conserved PDZ1 motifs (Figure. 16B). These findings therefore indicate that the binding
of different peptides has little effect on the PDZ1 overall fold, consistent with previous
studies showing that the localized changes at a few key positions within the PDZ fold
were responsible for dramatically altered PDZ binding specificity140. Indeed, significant
differences are observed only in the peptide-binding pocket, especially at PDZ residues
that are involved in recognition of different side chains at position -1 and -3 of the
peptide ligands. In particular, the structural alignments reveal that the Asn22 side chain
has two different orientations, while the conformation of the Glu43 side chain differs
among all four PDZ1 structures (Figure. 16B). Such structural differences have been
noted before and led to the conclusion that the conformational changes of Asn22 and
Glu43 underlay the PDZ1 flexibility to accommodate ligands with -1 side chains of
different hydrophobicity and polarity4.
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The availability of the PDZ1-CXCR2 structure, however, not just confirms the
above conclusion, but also has the potential to reveal differential -3 side chain
recognition, i.e., how PDZ1 differentiates CXCR2 Ser-3 from Asp-3 of CFTR, β2AR and
PDGFR. In this context, it is interesting to note that the most striking difference among
the PDZ1 complexes is the His29 side chain, which adopts two different conformations.
In PDZ1-CXCR2, the side chain of His29 is oriented toward the hydroxyl group of Ser-3,
participating in specific ligand interaction; whereas in other three complexes, the
imidazole ring of His29 points away from the bound ligands and does not engage in any
peptide recognition (Figure. 16B). Strikingly, this conformational change is accompanied
by large alteration in the Arg40 rotameric state, which rotates to make completely
different PDZ1-peptide interactions. In PDZ1-CFTR, PDZ1-β2AR, and PDZ1-PDGFR,
Arg40 is a key anchor residue for specific Asp-3 recognition and participates in direct
ligand binding1, 4. In PDZ1-CXCR2, due to steric effects, the reorientation of His29
forces the Arg40 side chain to kink outwards and prevents it from interacting with the
shorter side chain of Ser-3 (Figure. 16B). Therefore, these observed differences
demonstrate that the structural variability surrounding the peptide-binding pocket is
important for PDZ1 ligand specific interactions, and that the rotameric differences of a
few key residues constitute the basis for PDZ1 robustness to bind a diverse array of
functionally different proteins122, 140.
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Figure 16. Structural comparison of PDZ domains. (A) Superposition of the structures of
PDZ1-CXCR2 (purple; PDB code: 4JL7), PDZ1-CFTR (orange; PDB code: 1I92)1,
PDZ1-β2AR (cyan; PDB code: 1GQ4)4, and PDZ1-PDGFR (yellow; PDB code: 1GQ5)4.
PDZ domains are represented by ribbon, while residues in the ligands are displayed as
sticks. (B) Superposition of the PDZ1 ligand binding pockets. Both PDZ1 and ligand
residues are depicted by sticks and colored according to the scheme in Fig 3A. (C) Closeup views of structural differences of His29 (top) and Arg40 (bottom). The CXCR2
peptide is depicted by sticks overlaid with 2Fo − Fc omit map calculated at 1.16 Å and
contoured at 2.0 σ. (D) Superposition of NHERF1 PDZ1 (purple) and PDZ2 (pink; PDB
code: 2OZF) peptide binding pockets. CXCR2 peptide is shown in green and PDZ
residues are depicted by balls-and-sticks.
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CXCR2 Interacts with Both NHERF1 PDZ1 and PDZ2
The structural alignment reveals that NHERF1 PDZ1 and PDZ2 share highly
similar overall structures and also highly conserved ligand binding pockets (Figure. 16C).
The only notable difference in the ligand binding sites is residue 27, which is the His in
PDZ1 and Asn (residue 164) in PDZ2. It should be noted that this conserved substitution
maintains the amino functionality of the side chains, and thus, is not expected to disrupt
the observed polar interactions between the CXCR2 peptide and PDZ1 (Figure. 15A).
Based on that, we hypothesize that NHERF1 PDZ2 may also bind to CXCR2. Indeed, we
showed that CXCR2 interacts with both PDZ1 and PDZ2 in the GST-pulldown
experiments, with PDZ2 exhibiting higher binding affinities (Figure. 17). Specifically, we
overexpressed CXCR2 in HEK293 cells and then performed pulldown assays from cell
lysates using various GST-PDZ constructs. Whereas no CXCR2 was detected in the
control lane containing GST alone, significant amounts of CXCR2 were found in the
lanes containing PDZ1 domain (GST-PDZ1), PDZ2 domain (GST-PDZ2), and both PDZ
domains together (GST-PDZ1-PDZ2). To test whether the PDZ-CXCR2 interactions are
direct, we performed in vitro pulldown experiments with a biotinylated peptide
corresponding to the last 13 amino acids of CXCR2. Similar binding results were
observed in the experiments where CXCR2 interacts with both PDZ domains of NHERF1
(Figure. 17B).

Many other NHERF1 ligands, such as CFTR, PDGFR and PTH1R, were also
known to bind both PDZ1 and PDZ2 in vitro127, 141, 142, but in most cases, the biological
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significance of such bivalent interactions remains unknown. It has been shown that
bivalent binding was important for CFTR channel gating regulation, and disruption of the
PDZ2-CFTR interaction, but keeping the interaction between PDZ1 and CFTR intact,
was able to abolish the NHERF1 stimulatory effect on CFTR channel open probability143,
144

. In addition, it has been suggested that a single NHERF1 molecule could assemble a

PDGFR dimer and played a role in PDGFR signaling via stabilizing the ligand-induced
receptor dimerization145. Later studies, however, revealed that PDGFR signaling was
unexpectedly enhanced rather than impaired in NHERF1-null mouse embryonic
fibroblasts, suggesting quite a different role of this bivalent molecule in PDGFR
signaling regulation146. Remarkably, a recent article by Cardone et al. showed that
NHERF1 PDZ1 and PDZ2 domains differently regulated invadopodia and podosome
dynamics134, and suggested that the differential functions of two PDZ domains might be
dependent on their ability to interact with a unique array of functionally different
signaling molecules134. Based on that, it is reasonable to speculate that the ability of
CXCR2 to bind both NHERF1 PDZ domains may allow CXCR2 to operate in different
signaling networks, which might be a key functional trait that has evolved to deal with
the complexity of signaling transduction. While the biological impacts of this bivalent
binding are currently unknown, future studies should be directed toward evaluation of its
effects on CXCR2-mediated neutrophilic migration, receptor dimerization, CXCR2
internalization, and especially determining whether different NHERF1 PDZ domains
could mediate the assembly of distinct and specific CXCR2 signal transduction
complexes.
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Figure 17. CXCR2 interacts with both PDZ1 and PDZ2 of NHERF1. (A) GST pull-down
of CXCR2 with NHERF1. Lysates of HEK293 cells overexpressing HA-tagged CXCR2
were used as prey. GST fusion proteins of NHERF1 PDZ1, PDZ2, and PDZ1-PDZ2
were used as bait. GST alone served as a negative control. Binding experiments were
analyzed by SDS-PAGE and visualized by immunoblot using anti-HA antibodies. The
amount of beads-immobilized GST proteins in each reaction is shown in the lower panel.
(B) Biotin pull-down assays to detect direct interaction between CXCR2 and NHERF1.
A biotinylated peptide corresponding to the last 13 residues of CXCR2 was used as bait,
while purified GST-PDZ1, GST-PDZ2, GST-PDZ1-PDZ2 and GST alone as prey.
Binding was resolved by SDS-PAGE and immunoblotted with anti-GST antibodies. (C)
All experiments performed in (A) and (B) were repeated three times. The results were
quantified using the CCD gel imager (UVP Chemidoc) and presented as mean±standard
deviation. Top: GST pull-down of CXCR2 with NHERF1, and bottom: Biotin pull-down
of NHERF PDZ domains with the CXCR2 peptide.
Drug Design Perspective
Due to the exceptional importance of CXCR2 in inflammation and
tumorigenesis117, the structural determinants of the CXCR2-NHERF1 interaction may be
valuable in developing new methods and strategies for targeted drug discovery. For
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example, this information can be used to create new CXCR2 inhibitors that are potent
and specific to block the CXCR2-NHERF1 interaction. Such inhibitors could in turn have
a therapeutic potential in inhibiting neutrophil-driven inflammation by reducing
neutrophil recruitment and restoring neutrophils to the tissue clearance pathway of
apoptosis147. In this context, it is interesting to note that disruption of the CXCR2NHERF1 complex was sufficient to inhibit the IL-8-induced neutrophilic chemotaxis and
margination119. Therefore, small molecules and peptides that specifically block the
CXCR2-NHERF1 interaction could act as CXCR2 antagonists and could be useful in
attenuating the signaling activities of CXCR2 in various neutrophil-related inflammation
disorders, such as inflammatory bowel diseases, chronic lung inflammation, and
atherosclerosis119.

However, the commonality of peptide recognition at position 0 and -2 by class I
PDZ domains, together with NHERF1 capable of binding to a multitude of ligands
(Figure. 14C), poses a challenge for designing CXCR2 inhibitors that are specific to the
CXCR2-NHERF1 interface but do not cross-react with any of the other NHERF1mediated interactions. NHERF1, through a network of PDZ domain-mediated
interactions, regulates many cellular processes essential to normal physiological
functions, such as testicular differentiation, signal transduction, endosomal recycling,
membrane targeting, and hormone receptor desensitization148,

149

. Therefore, it is

conceivable that random targeting of NHERF1-ligand interactions by nonselective
inhibitors could disrupt the NHERF1 interaction network and leads to considerable risks
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with a diverse range of unwanted physiological and hormonal abnormalities. Regarding
this possibility, it is particularly important to note that contextual specificity plays a key
role in all peptide-mediated protein interactions136, suggesting that the ability to achieve
CXCR2 inhibitor selectivity is dependent on the identification and exploitation of
structural features that differentiate CXCR2 from other NHERF1 binding partners, and
on understanding how the peptide motif and context work in coordination to control the
specificity and formation of each crucial NHERF-scaffolded signaling complex. This
notion is consistent with accumulating evidence that the positions other than 0 and -2
make significant and variable contributions to both affinity and specificity of the PDZmediated interactions4,

124

. For example, recent large-scale PDZ specificity mapping

studies demonstrated that the PDZ domain family is surprisingly complex and diverse,
recognizing up to 7 C-terminal ligand residues and forming at least 16 unique specificity
classes across human and worm122. Furthermore, we recently showed that, although the
motif-contacting residues involved in CXCR2 binding are all conserved in NHERF1 and
PDZK1 (Figure. 14A), CXCR2 did not interact with PDZK1 in the in vitro GST pulldown assays119, reciprocally suggesting that high affinity CXCR2 binding and selection
by NHERF1 is also context dependent. Therefore, strategies aiming at exploiting
CXCR2-NHERF1 contextual interactions may represent a promising approach for the
development of small molecules that would selectively block this interaction and
specifically inhibit the neutrophil-driven inflammation. In this context, it is particularly
important that the ligand-specific structural principles that govern the NHERF1 targetselection diversity should be addressed in great detail.
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CHAPTER 5
New Conformational State of NHERF1-CXCR2 Signaling Complex Captured by
Crystal Lattice Trapping
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Abstract
NHERF1 is a PDZ adaptor protein that provides a scaffold for the assembly of
diverse signaling complexes and has been implicated in many cancers. However, little is
known about the mechanism responsible for its ability to bind to multiple targets.
Computational studies have indicated that PDZ promiscuity may be attributed to its
conformational dynamics, but experimental evidence for this relationship remains very
limited. Here we examine the conformational flexibility of the NHERF1 PDZ1 domain
using crystal lattice trapping via solving PDZ1 structure of a new crystal form. The
structure, together with prior PDZ1 structures of a different space group, reveals that 4 of
11 ligand-interacting residues undergo significant crystal packing-induced structural
changes. Most of these residues correspond to the residues involved in allosteric
transition when a peptide ligand binds. A subtle difference in peptide conformations
causes the same ligand to bind in slightly different modes in different crystal forms.
These findings indicate that substantial structural flexibility is present in the PDZ1
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peptide-binding pocket, and the structural substrate trapped in the present crystal form
can be utilized to represent the conformational space accessible to the protein. Such
knowledge will be critical for drug design against the NHERF1 PDZ1 domain,
highlighting the continued need for experimentally determined PDZ1-ligand complexes.

Introduction
The Na+/H+ exchanger regulatory factor 1 (NHERF1) is a multifunctional scaffold
protein that plays a central role in diverse cellular events through recruiting receptors,
transporters, and signaling molecules into specific functional complexes150. NHERF1
also plays a significant role in multiple cancers where its elevated expression correlates
with aggressive stage and poor overall prognosis134. The functional diversity of NHERF1
in normal and pathological conditions depends largely on its two PDZ (PSD-95/Discslarge/ZO-1) domains, PDZ1 and PDZ2, which are highly promiscuous and capable of
interacting with a large number of biologically different proteins150. To date, over 40
binding partners of NHERF1 have been identified; most of which are membrane
receptors and transporters, such as the interleukin 8 receptor beta (CXCR2), the cystic
fibrosis transmembrane conductance regulator (CFTR), the β2-adrenergic receptor
(β2AR), the platelet-derived growth factor receptor (PDGFR), and the parathyroid
hormone receptor (PTHR)119,

127, 128, 151, 152

. Through these PDZ-interacting proteins,

NHERF1 regulates many processes, including cell proliferation, invasion and migration,
signal transduction, and protein trafficking148, 149. Our recent studies showed that the PDZ
domains of NHERF1 bind CXCR2 in neutrophils, regulating neutrophil chemotaxis and
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directing neutrophils to sites of inflammation119. A similar interaction was observed for
pancreatic cancers, where disruption of this PDZ-mediated interaction was capable of
suppressing human pancreatic tumor growth in vivo152. These recent evidence suggests
targeting the PDZ-mediated NHERF1-CXCR2 interaction may represent a novel clinical
strategy, which could be valuable in the development of new treatments against
numerous neutrophil-dependent inflammatory diseases as well as pancreatic cancers148,
149

.

In general, PDZ domains mediate protein interactions by recognizing the Cterminal sequence of target proteins, and by binding to the targets through a canonically
and structurally-conserved PDZ peptide binding pocket121. Based on the residues at
positions 0 and -2 of the peptides (position 0 referring to the C-terminal residue), early
studies grouped PDZ domains into two major specificity classes: class I, (S/T)X(V/I/L)
(X denoting any amino acid); class II, (F/Y)X(F/V/A)

1, 123, 124

. However, growing

evidence indicates that PDZ specificity is unexpectedly complex and diverse, with the
PDZ domain family recognizing up to 7 C-terminal ligand residues and forming at least
16 unique specificity classes122. In addition, the complexity of PDZ-peptide interactions
is exemplified by the facts that many PDZ domains can bind to multiple ligands of
different peptide classes, and that single peptides are able to bind to distinct PDZ
domains122. This complex picture of PDZ-peptide interactions raises a challenging
problem regarding how PDZ domains, structurally simple protein interaction modules,
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achieve binding promiscuity and specificity concomitantly, the nature of which remains
obscure.

Because promiscuity and specificity have important implications in highly
selective drug design153, understanding the mechanism that determines PDZ interaction
with specific peptide sequences is a subject of intensive research. Recent binding
specificity studies of 157 mouse PDZ domains revealed that PDZ domains are evenly
distributed throughout selectivity space, suggesting that they have been optimized across
the proteome to minimize cross-reactivity154. The same study revealed a weak but
significant correlation between the pairwise sequence divergence of PDZ domains and
their divergence in ligand selectivities154. More recent specificity profiling studies with
91 point mutants of a model PDZ domain revealed that PDZ binding preference can be
influenced by multiple structural and chemical mechanisms involving both direct contacts
and cooperative, long-range effects, suggesting that PDZ specificity evolves rapidly, thus
enabling PDZ for robust interaction with many biologically distinct ligands122. Using
shotgun alanine scanning, another PDZ specificity study has yielded considerable
insights into the relationships between primary sequence and specificity140. This study
demonstrated that most of the alanine substitutions in HtrA1-PDZ are neutral with respect
to peptide-binding selectivity and only a subset of mutations, mostly within the canonical
PDZ binding pocket, affects its binding specificity140. Therefore, the results of these
studies have offered considerable information about how the sequence composition

98

determines PDZ specificity, and a coherent picture of their relationships is beginning to
emerge.

Despite the wealth of detail about PDZ specificity, the mechanism that determines
PDZ promiscuity still remains poorly understood, partly because it has been difficult to
explain PDZ promiscuity simply based on its sequence composition. It is important to
note that a number of computational and experimental studies have suggested the
conformational dynamics of PDZ domains may play a crucial role in ligand binding,
especially in determining binding promiscuity126,

155-157

. For example, molecular

dynamics simulation of 12 PDZ domains revealed that binding dynamics and entropy are
extremely variable not only across PDZ domains but also for the same PDZ domain
bound with different ligands155. This indicates that complex-specific dynamical or
entropic responses may form the basis for promiscuous binding and sustaining
promiscuity in highly selective PDZ-peptide interactions155. Another computational study
of five different PDZ domains came to similar conclusion. It revealed the existence of a
close relationship between intrinsic dynamics and binding promiscuity and suggested the
ability of PDZ domains to interact with multiple ligands requires the binding pocket to
adopt significantly different conformations126. In addition, based on differential domain
fluctuation profiles, the latter study also indicated that both induced fit and
conformational selection play roles in PDZ ligand binding, but the extent to which these
mechanisms are involved is highly variable across the PDZ domain family126.
Remarkably, recent NMR dynamics studies demonstrated that the ligand-bound
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conformation is already present in the conformational ensemble populated by unliganded
protein, suggesting the intrinsicality of protein to fluctuate between multiple conformers,
or conformational selection, might be the fundamental paradigm for promiscuous ligand
binding158-160. These studies made it apparent that detailed and comparative analysis of
PDZ conformational plasticity will be required to establish and illuminate the full range
of ligand promiscuity specified by the PDZ domain fold. A high-resolution structural
interpretation of individual conformational states should in turn provide considerable
insights into the mechanisms whereby the exquisite ligand promiscuity dictates the
diversification of biological functions.

In order to understand the promiscuity and specificity of the NHERF1 PDZ
domains, we have previously reported a high-resolution PDZ1 crystal structure in
complex with the CXCR2 C-terminal sequences151. We found that NHERF1 PDZ1 is
capable of assuming distinct conformational states when the structure of PDZ1-CXCR2
was compared to the structures of three other PDZ1 complexes, including PDZ1-CFTR,
PDZ1-PDGFR, and PDZ1-β2AR1, 4. Importantly, the complex-specific conformations
were found to be closely associated with the various characteristics of peptide ligands4,
151

, suggesting that PDZ1 promiscuity is facilitated by protein flexibility that allows

robust accommodation of peptides with distinct sequences. While these studies provided
valuable insight about PDZ1 promiscuity and flexibility, the questions still remain
concerning the dynamical features that control explicit binding of each of PDZ1 ligands
and whether NHERF1 function relies on PDZ1 conformational diversity. Additionally,
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we are still far from a complete description of PDZ1 conformational space, and the
amount of available PDZ1 structures may represent only a tiny fraction of the entire
ensemble126, 155-157. It is conceivable that limited numbers of PDZ1 structures could limit
their usefulness in rational drug design owing to large unexplored conformational space
that may compensate drug discovery efforts for potency and selectivity. Moreover, the
lack of a complete picture of PDZ1 conformational space could lead to an incomplete
understanding of the complex relationship between PDZ1 conformational dynamics and
the promiscuous nature of its substrate specificity. In these regards, we here present a
new conformational state of PDZ1 by solving the structure of the PDZ1-CXCR2 complex
in a new crystal form. Multiple PDZ1 conformations observed in the present crystal form
and another crystal form reported previously151 provide an additional insight into PDZ1
conformational dynamics and a structural explanation for how PDZ1 is able to bind to
different ligands. Alternatively, the variations in the structures of different crystal forms
raise the challenge for selective drug design, emphasizing the need for obtaining X-ray
crystal structures of various PDZ1 conformational states to inform the drug design
process.

Materials and Methods
Protein Expression and Purification
A DNA fragment encoding the human NHERF1 PDZ1 (residues 11–94), and
having the C-terminal extension TSTTL that corresponds to residues 356–360 of human
CXCR2, was amplified using PCR and cloned in the pSUMO vector151. The resulting

101

clone containing a N-terminal His6-SUMO tag was transformed into Escherichia coli
BL21 Condon Plus (DE3) cells for protein expression. The transformants were grown to
an OD600 (optical density at 600 nm) of 0.4 at 37 °C in LB medium, and then induced
with 0.1 mM isopropylthio-β-D-galactoside and grown an additional 16 hours at 15 °C.
The cells were harvested by centrifugation and lysed by French Press. The soluble
fraction was then subjected to Ni2+ affinity chromatography purification, followed by the
cleavage of the His6-SUMO tag with yeast SUMO Protease 1. PDZ1 was separated from
the cleaved tag by a second Ni2+ affinity chromatography and further purified by sizeexclusion chromatography. Finally, the protein was concentrated to 40–50 mg/ml in a
buffer containing 20 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM β-mercaptoethanol
(BME), and 5% glycerol.

Crystallization, Data Collection and Structure Determination
Crystals were grown by the hanging-drop vapor-diffusion method by mixing the
protein (~25 mg/ml) with an equal volume of reservoir solution containing 100 mM
sodium acetate, pH 4.8, 0.2 M ammonium acetate, 25% PEG4000 at 20 °C. Crystals
typically appeared overnight and continued to grow to full size in 3-4 days. Before X-ray
diffraction data collection, crystals were cryoprotected in a solution containing mother
liquor and 25% glycerol and flash cooled in liquid nitrogen. The data were collected at
100 K at beamline 21-ID-F at the Advanced Photon Source (Argonne, IL) and processed
and scaled using the program HKL200067. Crystals belong to space group P21 with unit
cell dimensions a = 26.6 Å, b = 45.5 Å, c = 33.4 Å, β = 109.7°, and one molecule in the

102

asymmetric unit. The structure was solved by the molecular replacement method with
program PHASER96 using the P3121-PDZ1 structure (PDB code: 4JL7) as a search
model. The structure modeling was carried out in COOT69, and refinement was
performed with PHENIX97. The riding hydrogen and ADP features were included in the
refinement, and no ADP restraint was employed. The final models were analyzed and
validated with Molprobity99. The ADPs were analyzed using ANISOANL161 and the
PARVATI server162. All figures of 3D representations of the P21-PDZ1 structure were
made with PyMOL.

Protein Data Bank Accession Number
Coordinates and structure factors have been deposited in the Protein Data Bank
with accession number 4MPA (P21-PDZ1) and 4N6X (P3121-PDZ1).

Results
New Crystal Form of PDZ1-CXCR2 Complex
Alternative crystal forms can trap a protein in different conformational states,
providing snapshots of the conformations accessible to the protein163-165. To reveal
possible PDZ1 conformational states and how these may be important for PDZ1
promiscuity, we sought to use this well-recognized strategy to improve our understanding
on PDZ1 conformational dynamics. Previously, we crystallized the PDZ1-CXCR2
complex in the P3121 space group and have determined its structure at 1.16 Å resolution
(P3121-PDZ1)151. In the current study, by using different crystallizing precipitant under
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Table 4. Crystallographic data and refinement statistics
Space group
Cell parameters (Å)
a
b
c
Wavelength (Å)
Resolution (Å)
Rmergeb
Rmeasc
CC1/2d
Redundancy
Unique reflections
Completeness (%)
〈I/σ〉
Wilson B-factor
Refinement
Resolution (Å)
Molecules/AU
Rworke
Rfreef
Ramachandran plot by Molprobity
Residues in favored region
Residues in allowed region
RMSD
Bond lengths (Å)
Bond angels (°)
No. of atoms
Protein (residues 9-94)
Peptide (residues 95-99)
Water
Chloride
Acetate
B-factor (Å2)
Protein
Peptide
Water
Chloride
Acetate
a

P21
26.6
45.5
33.4
0.97856
45.5-1.1 (1.16-1.10)a
0.024 (0.180)
0.034 (0.248)
0.999 (0.951)
3.7 (2.4)
30032
97.7 (86.0)
24.8 (4.5)
8.2
25.9-1.10
1
0.143 (0.158)
0.156 (0.193)
97.9%
2.1%
0.010
1.2
679
39
161
1
4
14.8
9.7
26.3
16.2
23.4

Numbers in parentheses refer to the highest resolution shell.
Rmerge=Σ|I-〈I〉| / ΣI, where I is the observed intensity and 〈I〉 is the averaged intensity of multiple
observations of symmetry-related reflections.
c
Rmeas=Σ[(n/n-1)]1/2Σ|I-〈I〉| / ΣI, where n is the number of observations of a given reflection.
d
Half-dataset correlation coefficient.
e
Rwork= Σ|Fo-Fc| / Σ|Fo|, where Fo is the observed structure factor, Fc is the calculated structure factor.
f
Rfree was calculated using a subset (5%) of the reflection not used in the refinement.
b
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similar pH, we obtained a new crystal form that diffracted to 1.10 Å resolution. The new
crystal belongs to the P21 space group (P21-PDZ1), and the structure was solved by
molecular replacement. The model was refined to Rwork of 14.3% and Rfree of 15.6%, and
the validation of its stereochemistry using Molprobity99 showed that 97.9% of the
residues are in the most favored regions, 2.1% in the additional allowed regions, and
0.0% in the disallowed regions (Table 4).

Both crystal forms contain one molecule per asymmetric unit, but their crystal
packing environments differ significantly. For P3121 the distinctive packing pattern is
manifested by linear stacking of PDZ1 complexes, hexagonal lateral association, and the
existence of large solvent channels across the crystal (Figure. 18A). In the case of P21,
the PDZ1 complexes are stacked in a staggered arrangement, displaying a densely
packed, flattened configuration (Figure. 18B). Consistent with the packing environments,
the solvent content in the P3121 crystal form is higher than P21-PDZ1, ~50% compared
to ~37%. However, analysis of crystal contacts reveals that there are more intimate
packing interactions in the P3121 crystal. For example, with distances of less than 3.5
Ådefined as contacts, P3121 has 128 crystal contacts with symmetry-related molecules,
whereas the P21 crystal has only 82 such contacts. Accessibility calculation with
AREAIMOL161, 166 shows that 2608 Å2 of protein surface is buried by symmetry-related
molecules in P3121-PDZ1, compared to only 2382 Å2 buried in P21-PDZ1. Thus, it
appears that the protein molecules in the P21 crystal pack more loosely than in P3121PDZ1, though it has a relatively lower solvent content. Furthermore, their distinct
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Figure 18. Crystal packing differences between two crystal forms. (A) Section of
the crystal lattice of P3121-PDZ1 and (B) P21-PDZ1. The unit cell is shown as a
red box, with the origin and axes labeled. PDZ1 is shown as a Cα trace, with red
standing for a reference molecule and green the symmetry-related molecules. (C)
Surface representation of crystal contacts around the ligand-binding site of
P3121-PDZ1 and (D) P21-PDZ1. The surface is colored in blue if the distance to
symmetry-related molecules is 3.5 Å or less and is colored in green otherwise.
PDZ1 is depicted as ribbon and the bound CXCR2 peptide is labeled and
represented by sticks.

packing environments are highlighted by strikingly large differences in their crystal
contact surfaces. For all of the 128 contacts sites found in P3121, there is no
corresponding contact surface with equivalent residue composition in P21-PDZ1 (Figure.
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18C and 18D). This difference provides the basis for us to utilize crystal packing in
understanding PDZ1 conformational dynamics and should allow the capture of different
conformational substrates.

Distinct PDZ1 Conformational States
Different crystal packing observed in P21-PDZ1 and P3121-PDZ1 indeed causes
significant differences in the ligand-binding pocket, but does not alter the overall fold of
the protein (Figure. 19). In both crystal forms, PDZ1 adopts a conserved fold
characterized by six β strands (β1–β6) and two α-helices (αA and αB). Superposition of
the two structures reveals a high degree of overall structural similarity, with the rms
(root-mean-square) differences of 0.91 Å for main chains and 1.46 Å for side chains. In
addition, the crystal packing has little effect on the overall ligand interaction mode, as in
both cases the CXCR2 peptide inserts between β2 and αB as an extra β-strand and the
main-chain rms difference between the bound peptides is only 0.17 Å (Figure. 19B).
Moreover, closer inspection of the PDZ1-CXCR2 interactions reveals that the specific
ligand recognition modes at the peptide positions 0 and -2 are virtually indistinguishable.
In both crystal forms, the side chain of Leu0 is nestled in a deep hydrophobic pocket
formed by structurally identical residues, including Tyr24, Phe26, and Leu28 from β2,
and Val76 and Ile79 from αB (Figure. 19D). At the ligand position -2, the side chain
hydroxyl of Thr-2 in each structure hydrogen bonds to the imidazole ring of His72, with
the side chain aliphatic carbon making contact to the structurally conserved residue Val76
(Figure. 19E). It should be noted that all these CXCR2 interacting residues are spared
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from the crystal packing in both crystal forms, consistent with their spatially buried
natures in the PDZ1-peptide complexes151.

Figure 19. Structural similarities of two crystal forms. (A) Ribbon view of overall P21PDZ1 structure. PDZ1 is shown in green and the CXCR2 peptide shown in blue.
Secondary structures of PDZ1, α-helices and β-strands, are labeled and numbered
according to their position in the sequence. (B) Superposition of P21-PDZ1 (green) and
P3121-PDZ1 (magenta). (C) Stereo view of the PDZ1-CXCR2 interaction in P21-PDZ1.
The PDZ1 residues are represented by sticks with their carbon atoms colored in green.
The CXCR2 peptide is depicted by sticks overlaid with 2Fo − Fc omit map calculated at
1.1 Å and contoured at 1.5 σ. Hydrogen bonds are illustrated as orange broken lines. (D)
Superposition of the Leu0 and (E) Thr-1 recognition regions. Both P21-PDZ1 and P3121PDZ1 are depicted by sticks and colored according to the scheme in Figure B and C.
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In contrast to the ligand recognition at positions 0 and -2, distinct conformations
between the two forms of PDZ1 structures are observed in regions that are responsible for
interactions with -1 and -3 residues. Notably, the residues at these two ligand positions
are highly variable across natural PDZ1 binding targets, exemplifying its ability to bind
multiple targets151. Thus, understanding the conformational dynamics that governs the
specific interactions with residues -1 and -3 should be key to understanding the
underlying mechanisms of PDZ1 promiscuity. Specifically, the PDZ1 residues exhibiting
large conformational differences between the two crystal forms include His27 and His29
from β2, Arg40 from β3, and Glu43 from the loop following β3 (Figure. 20A). These
residues are known to be important for -1 and -3 residue recognition, three of which
(His29, Arg40, and Glu43) have been shown to undergo a large conformational change
upon binding to different ligands4, 151. Remarkably, their differences in the conformations
appear to be well correlated with differential crystal packing lattices, highlighting their
adaptability to different environments that may be essential for PDZ1 promiscuity. In
particular, the greatest difference between the ligand binding sites of the two PDZ1 forms
is at residue Arg40, where the rms deviation of the main chain atoms is 0.02 Å and, for
side chain atoms, 0.59 Å (Figure. 20B and 21). This large variation in Arg40
conformations is closely associated with the large differences in its crystal packing
environments. In P3121-PDZ1, the side chain atoms of Arg40 make a hydrogen bond to
Met10 and van der Waals contacts with the Pro12 side chain of a neighboring molecule.
In P21-PDZ1, only the Nη2 atom of Arg40 is within 4 Å distance to a neighboring Thr71,
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Figure 20. Different Arg40 conformations of two crystal forms. (A) Overall view of
conformational differences in the peptide-binding pocket. P21-PDZ1 and P3121-PDZ1
are superimposed and colored according to the scheme in Figure 2. (B) Arg40 crystal
contacts in P21-PDZ1 (top) and in P3121-PDZ1 (bottom). Symmetry-related molecules
are represented by ribbons and sticks with their carbon atoms colored in cyan. (C)
Thermal ellipsoid representation of Arg40 of P21-PDZ1 (top) and P3121-PDZ1
(bottom). Carbon atoms are colored gray, nitrogen atoms blue, and oxygen atoms red.
Thermal ellipsoids are contoured at the 50% probability level.
no any intermolecular contacts were observed below 3.5 Å. As a result of different crystal
packing, Arg40 has very different rotameric conformations in the two crystal structures.
In P3121-PDZ1, the side chain of Arg40 is oriented toward the hydroxyl group of Ser-3,
whereas in P21-PDZ1, its guanidinium points away from the bound ligand, adopting a
conformation corresponding to ~ 90° rotation around the Cβ-Cγ bond of the side chain
(Figure. 20B). In both crystal forms, Arg40 does not make contact with the CXCR2
peptide, whereas in other PDZ1 structures bound with different peptides1, 4, it is a key
anchor residue for specific Asp-3 recognition and engages in direct ligand binding.
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Notably, a different rotameric state was assumed in the latter complexes, which allows
Arg40 binding to the ligands with the longer side chain at the -3 position151.

In addition to the conformational change, the intrinsic dynamics of Arg40 is
different between the two crystal forms, and is significantly perturbed by the crystal
packing. In P3121-PDZ1, the mean anisotropy of Arg40 atoms is 0.337 (σ=0.070), which
is considerably more anisotropic than that in P21-PDZ1 (A=0.489, σ=0.133) (Table 5).
The majority of the largest anisotropic differences are located in the main chain region,
which appear to correspond to the different crystal packing environments (Figure. 20C).
In P3121-PDZ1, the thermal ellipsoids for the main chain atoms of Arg40 are prolate,
with the longest principal axis oriented roughly parallel with the side chain direction,
indicating that displacements of the Arg40 backbone are least constrained along the side
chain and most constrained in directions orthogonal to the side chain. This result
contrasts sharply to the more isotropic displacements in P21-PDZ1, consistent with the
extensive crystal packing and the fact that the orientations of the principal axes of the
side chain fluctuations correspond closely to those of nearby neighboring atoms.
Together, our crystallographic analysis demonstrates that residue Arg40 is intrinsically
flexible, capable of exploring large conformational space, or visiting different
conformations required for binding multiple partners.

Another large conformational difference occurs at His29, a residue that plays a
key role in Ser-3 recognition151. This difference is not the direct result of crystal packing,

111

Table 5. Isotropic B-factor and anisotropy

a
Numbers in parentheses refer to standard deviation.
b
The mean anisotropy A is defined as the ratio of the smallest to the largest eigenvalue of U, where U is
ADP tensor.
Ser-3:1 conformation 1; Ser-3:2 conformation 2.
c

!
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as neither crystal form involves His29 in the lattice interface, and the distance from His29
to the nearest neighboring atom is 4.6 Å for P3121-PDZ1 and 6.2 Å for P21-PDZ1.
However, through altering intramolecular interactions, the crystal packing has an indirect
impact on His29 conformation. In particular, different His29 structures in different
crystal forms are the result of altered local environments with altered Arg40
conformations (Figure. 21 and 22A). In P3121-PDZ1, the imidazole ring of His29 is held
down by the guanido group of Arg40 via parallel stacking interactions, whereas in P21PDZ1, the packing-induced reorientation of the Arg40 side chain leads to breakage of
such contacts, allowing His29 to adopt a more relaxed, ~25º upward-tilted rotamer. In
both crystal forms, residue His29 maintains direct hydrogen bonding to the Ser-3
hydroxyl, but this is achieved with a concerted change in the peptide structure.
Specifically, the movement of the His29 side chain induces a corresponding movement in
the side chain of Ser-3, which preserves the His29/Ser-3 contacts and ligand specific
recognition (Figure. 22A). Note the interaction of His29 with the -3 residue is dependent
on the types of ligands; when binding to different ligands, the side chain of His29 can
adopt very different conformers151. For example, in the PDZ1-CFTR complex1, the side
chain of His29 is completely oriented away from the CFTR peptide, adopting a
conformation that is unable to interact with the ligand (Figure. 22A). A similar conformer
has been observed in PDZ1-β2AR and PDZ1-PDGFR4, where the -3 residue (Asp-3) of
both complexes is common to the PDZ1-CFTR complex. In addition, the intrinsic
dynamics of His29 is discernible from the anisotropic displacement parameters (ADPs)
of the structures. The mean anisotropy of His29 in the two crystal forms are very similar,
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Figure 21. Electron density of
selected residues. The left panel,
P21-PDZ1; the right panel,
P3121-PDZ1.
Residues
are
depicted by sticks overlaid with
2Fo−Fc omit map calculated at
1.1 Å for P21-PDZ1 and 1.16 Å
for P3121-PDZ1, and contoured
at 1.5 σ.
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0.484 (σ=0.174) for P21-PDZ1 and 0.470 (σ=0.086) for P3121-PDZ1. However, the
anisotropy of the main chain atoms and the side chain atoms is inversely different (Table
5). In P21-PDZ1, His29 exhibits the higher main chain anisotropy, the principle axes of
which match excellently with the direction of the displacements deduced from the
structural alignment (Figure. 22F). This indicates that His29 has an intrinsic propensity to
undergo this movement. The higher side chain anisotropy of His29 in P3121-PDZ1
appears to be related to the Arg40/His29 interaction, as the similar ADP magnitudes and
orientations are observed for the Arg40 guanidinium and the His29 imidazole ring. These
findings indicate that similar to Arg40, His29 is also intrinsically flexible and contributes
to ligand specific binding and recognition.

Intriguingly, the peptide recognition by His29 and Arg40 appears to be mutually
exclusive, as they occupy the overlapping space when binding to specific ligands. For
instance, in PDZ1-CFTR, the interaction between Arg40 and Asp-3 induced steric effects
that prevented His29 from ligand binding1, 4. In PDZ1-CXCR2, binding of His29 to Ser-3
caused a “kink” in Arg40’s side chain resulting in the effective blockage of the Arg40CXCR2 interaction151. This mutually exclusive peptide recognition may be advantageous,
as the combined effects of individual recognition may increase PDZ1 robustness of
ligand binding, or its capacity to interact with multiple ligands. The blend of His29 and
Arg40 chemical properties, including hydrogen bonding, aromaticity, charge, and their
intrinsic flexibility, may allow PDZ1 recognition of different -3 side chains. Interestingly,
peptide affinity selection experiments showed that PDZ1 has no apparent amino acid
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preference for -3 position of peptides, capable of binding the peptides with -3 side chains
of different size and polarity137. These suggest PDZ1 promiscuity may be due to
multiplicity of possible binding modes that use different structural elements for binding
structurally different ligands. They also indicate that the functional interplay between
different peptide recognition residues requires a flexible binding pocket and the ability of
this pocket to adopt significantly different conformations.

The third notable conformational difference between the two crystal forms is at
Glu43, which, together with His29 and Arg40, provides evidence that substantial
structural flexibility is present in the PDZ1 peptide-binding pocket. Specifically, in
P3121-PDZ1, Glu43 is not engaged in any crystal contacts, having an upward-folded,
solvent-pointing side-chain conformation (Figure. 22B and 21). In contrast, in P21-PDZ1,
due to the contact with the Arg87 guanidinium of a neighboring molecule, the side chain
of Glu43 adopts a distinct conformation that stretches out towards the bound ligand. This
stretched conformation and its Arg-interacting ability, are reminiscent of PDZ1-CFTR
interaction. Similar Glu43 conformation observed in the PDZ1-CFTR structure is
required for specific binding with the Arg-1 of the ligand1. Intriguingly, comparing the
structures of PDZ1-CFTR and P21-PDZ1 reveals that the positions of Arg-1 and Arg87
are completely different from one another, and they show no spatial overlap, approaching
Glu43 from opposite directions (Figure. 22B). As a result, significant differences exist in
the salt bridge interaction scheme between the two crystal forms. In PDZ1-CFTR, the
Oε2 atom of Glu43 makes bifurcated hydrogen bonds with Nε and Nη2 of Arg-1,
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whereas in P21-PDZ1, the carboxylate oxygens of Glu43 are involved in separate
hydrogen bonding to Nη1 and Nη2 of Arg87. This difference indicates that the stretched
Glu43 conformation adopted in P21-PDZ1 may be robust in Arg recognition, capable of
binding Arg with different orientations. This conclusion is consistent with affinity
selection experiments that showed NHERF1 PDZ1 prefers ligands with Arg at the -1
position, and the affinity of the PDZ1-ligand interaction can be reduced by mutation of
Arg to Ala, Phe, Leu, or Glu1, 137. Given the recognized importance of Glu43 in peptide

Figure 22. Conformational differences of His29, Glu43, and His27 between two crystal
forms. (A) Superposition of His29 of P21-PDZ1 (green), P3121-PDZ1 (magenta), and
PDZ1-CFTR (yellow). (B) Comparative view of Glu43 of P21-PDZ1 and P3121-PDZ1
shown together with P21-PDZ1 symmetry-related molecules (top); superposition of
Glu43 of P21-PDZ1 and PDZ1-CFTR (bottom). (C) Superposition of His27 of P21-PDZ1
and P3121-PDZ1. Hydrogen bonds are illustrated as orange broken lines, and residues
from the symmetry-related molecules are colored in cyan. (D) Left: dual positioning of
His27 of NHERF2 PDZ1 (PDB code: 2OCS) and right: superposition of His27 of P21PDZ1 (green) and NHERF2 PDZ1 (orange). (E) Superposition of His27 of P3121-PDZ1
and PDZ1-CFTR. (F), (G), and (H) Thermal ellipsoid representation of His29, Glu43,
and His27 of P21-PDZ1 (top/left) and P3121-PDZ1 (bottom/right).

117

recognition1, together with its ability to adopt different conformations upon binding
different ligands151, the crystal packing-induced conformational change in Glu43
provides further evidence for its structural adaptability, consistent with general
proposition that PDZ flexibility contributes to PDZ promiscuity. More evidence in favor
of this interpretation is provided by the observation that the crystal packing has a
significant impact on the Glu43 anisotropic displacement parameters. In both crystal
forms Glu43 exhibits strong anisotropy (P21: A=0.319; P3121: A=0.352), but the nature
and orientations of their ADPs are discernibly different. In P3121-PDZ1, the ADP
orientations of the Glu43 atoms are not harmonized, whereas in P21-PDZ1, the principal
axes of the uniformly oriented ellipsoids correlate with the direction of the neighboring
Arg87 fluctuations, indicating the dynamic adaptation of Glu43 to different crystal
packing environments (Figure. 22G).

Finally, the flexible nature of the PDZ1 peptide-binding pocket is evident in the
observation that His27, which packs against -1 residue of the ligand, has different
conformations in different crystal forms. The differences include a tilt of the side chain
by 12° along the ligand and a 180° flip of the imidazole ring around the Cβ-Cγ bond
(Figure. 22C and 23). As a result of this reorientation, the imidazole ring is 1.0 Å closer
to Ser-3 in P21-PDZ1 than in P3121-PDZ1, and there is an overall 2.3 Å displacement
between its Nε2 atoms. Note that the flip of the His27 imidazole ring does not
significantly affect the His27/Thr-1 interaction, as the plane of the imidazole ring in the
two crystals is similarly oriented after flipping, and the σ-π stacking interaction between
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Figure 23. Electron density of His27 at high contour level. The left panel, P21-PDZ1;
the right panel, P3121-PDZ1. His27 is depicted by sticks overlaid with 2Fo−Fc omit
map calculated at 1.1 Å for P21-PDZ1 and 1.16 Å for P3121-PDZ1. The maps are
contoured at 5.0 σ, which reveal the densities at the position of nitrogen atoms are
stronger than the densities at the position of carbon atoms (Nε2 vs. Cε1; Nσ1 vs.
Cσ2). The B factors of the side chain atoms are shown in parentheses after the atom
names.
His27 and the Thr-1 hydroxyl is essentially independent of altered Nε2 positions.
Nonetheless, the difference in Nε2 positioning is a manifestation of different crystal
packing environments. In both crystal forms, the imidazole ring of His27 is involved in
crystal contacts but interacts with different symmetry-related residues. In P3121-PDZ1,
the Nε2 atom of His27 makes a hydrogen bond with the side chain Oε1 of Glu68,
whereas in P21-PDZ1, it is hydrogen-bonded to the equivalent oxygen from Glu61. As
shown in structure alignment, the side chain of Glu61 is similar in orientation to Glu68,
but slides more than 5 Å along the peptide binding cleft (Figure. 22C). Remarkably, the
direction of this shift corresponds to the direction of the His27 conformational change,
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suggesting the intrinsic flexibility of His27 that has the ability to adapt to different
environments. This conclusion is supported by the observed anisotropic displacement
parameters of His27 that differ dramatically between the two crystal forms (P21:
A=0.608; P3121: A=0.330), and by the observation that the principle axes of the His27
ADPs correspond to the direction of the predicted structural changes (Figure. 22H). The
intrinsic flexibility of His27 is also evident from prior findings that the His27 of
NHERF2 PDZ1 shows dramatically double conformations; one conformer stacks with -1
residue and the other simultaneously interacts with both -1 and -3 residues of a ligand
(Figure. 22D). Because NHERF2 PDZ1 His27 corresponds to NHERF1 PDZ1 His27, this
implies that the conserved His27 is capable of exploring a large conformational space for
promiscuous binding of various peptide sequences. It is intriguing to note the
conformations of His27 are different when NHERF1 PDZ1 binds to different ligands. In
PDZ1-CFTR, -β2AR, and -PDGFR, the conformations of His27 are highly
superimposable, making a direct hydrogen bond to the common -3 residue (Asp-3) and a
ligand-indiscriminative contact with the Cβ atom of the -1 side chain (Figure. 22E). In
contrast, in PDZ1-CXCR2 (P3121-PDZ1), the imidazole ring of His27 rotates 20°to
accommodate the Thr-1 hydroxyl, and is positioned 0.5 Å further from -3 position of the
ligand due to the lack of specific hydrogen binding with the shorter Ser-3 side chain.
These differences reflect the relationship between His27 conformations and PDZ1
promiscuity as well as the importance of His27 flexibility in binding different ligands.

Different Modes of CXCR2 Peptide Interaction
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One notable difference between the peptides is at the Ser-3 side chain, which
adopts a double conformation in P21-PDZ1, but only one conformation in P3121-PDZ1
(Figure. 24). This difference indicates that similar to PDZ1, the bound ligand also
exhibits significant flexibility, capable of assuming different conformations in different
environments. Specifically, a 130° rotation around the Cα-Cβ bond relates the two Ser-3
conformations present in the P21 crystal (Figure. 24). One conformation is similar to the
one observed for P3121-PDZ1 (conformation 1), while the other represents a new
conformer with the side chain pointing to the opposite direction of the ligand
(conformation 2). In P21-PDZ1, the two Ser-3 conformers are involved in completely
different interaction networks resulting in two distinct modes of interaction with PDZ1.
For conformation 1, the hydroxyl group of Ser-3 hydrogen bonds to the His29 imidazole
ring, whereas in conformation 2, the Ser-3 side chain is stabilized by a van der Waals
contact to the His27 Cδ2 atom and a hydrogen bond to a symmetry-related neighboring
residue (Glu61) (Figure. 21 and 24A). Intriguingly, conformation 2 also engages in
intrapeptide interaction and forms a water-mediated hydrogen bond with the Thr-1 side
chain hydroxyl. It appears this dual positioning occurring in P21-PDZ1 but not in P3121PDZ1 is due to the dramatic differences in crystal packing between the two crystal forms.
In P21-PDZ1, conformation 1 is not involved in any crystal contacts, whereas in P3121PDZ1, the tight packing between Ser-3 and Val91 may restrict the Ser-3 conformational
flexibility and impedes the possible rotation of its side chain (Figure. 24C). This
interpretation is supported by the fact that the axes of Ser-3 and Val91 fluctuations
remarkably match with each other in P3121-PDZ1, whereas the lack of the crystal contact
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Figure 24. Distinct modes of CXCR2
peptide interaction. (A) Double
conformation of Ser-3 in P21-PDZ1.
Residues of the CXCR2 peptide are
represented by sticks with their carbon
atoms colored in blue. PDZ1 residues
are shown in green, while its
symmetry-related residue is shown in
cyan. Orange broken lines depict
hydrogen bonds, and the labels I and
II indicate individual conformers of
Ser-3 double conformation. (B)
Superposition of the CXCR2 peptides
of P21-PDZ1 (blue) and P3121-PDZ1
(magenta). (C) Ser-3 crystal contacts
in P3121-PDZ1. (D) Thermal ellipsoid
representation of Ser-3 interaction in
P21-PDZ1 (top) and P3121-PDZ1
(bottom).

in P21-PDZ1 results in apparently coupled motion between Ser-3 and His29, which is not
found in P3121-PDZ1 (Figure. 24D). Together, these observations provide some evidence
that the intrinsic dynamics of the peptide ligand allows for interactions with different
peptide recognition residues. While the functional significance of this dynamical
response is unknown, future studies should be directed toward evaluation of its effects on
PDZ specificity and promiscuity; especially to determine whether the peptide flexibility
is important for single peptides to bind to distinct PDZ domains. It is of particular interest
to note the recognition of a peptide-loaded MHC molecule (major histocompatibility
complex) by the cognate T-cell receptor depends on the dynamics properties of the
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peptides, and differential peptide flexibility resulting from MHC polymorphisms can
broaden and expand T-cell receptor reactivity108, 167.

Discussion
That different PDZ1 conformations are captured by different crystal forms is not
surprising in itself, but to the extent it suggests the conformational space available to
certain regions of the protein. The set of different crystal structures is thus particularly
informative since it may represent different PDZ1 conformational states and reflects the
protein’s functional dynamics. One can argue that none of the PDZ1 crystal structures
correspond exactly to native substrates because of the influence of crystal packing
artifacts. Although this concern is likely to be somewhat valid, analysis of thermal factors
of nonisomorphous lysozyme structures suggests that the crystal lattice does not just
force some random conformational changes onto the molecule, but rather the molecule
moves along essential eigenvectors to adapt to different lattice environments168,

169

.

Furthermore, the agreement of the residues undergoing the packing-induced
conformational change with the residues involved in allosteric transition in response to
ligand binding is in support of use of crystal forms for consolidating PDZ1 structural
data, or gaining insights into potential ligand binding mechanisms (Figure. 3). Thus the
present P21 crystal form plus the four original liganded structures in the P3121 space
group provide in total five independent views of PDZ1 bound to its targets. Although
these structures likely account for only a tiny portion of the entire conformational space,
they allow us to at least tentatively begin to sketch the mechanism that describes how the
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protein works, and provide the basis for consideration of the PDZ1 structural dynamics
and the mechanism by which PDZ1 flexibility contributes to PDZ1 promiscuity. On the
other hand, given the exceptional importance of NHERF1 in tumorigenesis and
inflammation119, 134, 152, the knowledge of individual PDZ1 conformational states may be
valuable in developing new methods and strategies for selective drug design. For
instance, this information can be used to describe binding site flexibility that may allow
for accurate modeling of PDZ1-inhibitor interactions. The information also allows for the
use of ensemble docking in compound screening, and may contribute to druggable hotspot identification, and the designing of highly selective compounds170,

171

. Taken

together, the collection of available PDZ1 structures provides insight into the PDZ1
conformational dynamics and the structural explanations of how PDZ1 is able to bind to
different ligands. It is no doubt that further understanding of the rules that underlying the
ligand-binding site dynamics will benefit from continued studies of PDZ1 liganded
structures in different crystal forms.
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CHAPTER 6
Crystallographic Analysis of NHERF1-PLCβ3 Interaction Provides Structural Basis
for CXCR2 Signaling in Pancreatic Cancer

*Published in Biochemical and Biophysical Research Communication 2014 Apr
4;446(2):638-43. doi: 10.1016/j.bbrc.2014.03.028. All authors agreed with including their
work in this dissertation.

Abstract
The formation of CXCR2-NHERF1-PLCβ3 macromolecular complex in
pancreatic cancer cells regulates CXCR2 signaling activity and plays an important role in
tumor proliferation and invasion. We previously have shown that disruption of the
NHERF1-mediated CXCR2-PLCβ3 interaction abolishes the CXCR2 signaling cascade
and inhibits pancreatic tumor growth in vitro and in vivo. Here we report the first crystal
structure of the NHERF1 PDZ1 domain in complex with the C-terminal PLCβ3
sequence. The structure reveals that the PDZ1-PLCβ3 binding specificity is achieved by
numerous hydrogen bonds and hydrophobic contacts with the last four PLCβ3 residues
contributing to specific interactions. We also show that PLCβ3 can bind both NHERF1
PDZ1 and PDZ2 in pancreatic cancer cells, consistent with the observation that the
peptide binding pockets of these PDZ domains are highly structurally conserved. This
study provides an understanding of the structural basis for the PDZ-mediated NHERF1-
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PLCβ3 interaction that could prove valuable in selective drug design against CXCR2related cancers.

Introduction
CXC chemokine receptor 2 (CXCR2) is a G protein-coupled receptor that is
activated by binding to the chemokine Gro-α, Gro-β, Gro-γ, ENA-78, GCP-2, IL-8, or
118

NAP-2

. CXCR2 mediates neutrophilic migration and plays critical roles in the

positioning of oligodendrocyte precursors in developing spinal cord

114, 115, 119

. This

receptor also functions in angiogenesis and wound healing and contributes to both
spontaneous and inflammation-driven tumorigenesis

114, 116, 117

. Growing evidence

suggests that CXCR2 signaling promotes pancreatic cancer progression where its
elevated expression correlates with aggressive stages and poor overall prognosis in
patients

172, 173

. More recent studies indicate that CXCR2 is expressed in various

pancreatic ductal adenocarcinoma (PDAC) cell lines and enhances cell proliferation and
survival via the autocrine or paracrine effect 152, 174, 175. These findings imply that CXCR2
could be an attractive drug target for developing targeted treatment for pancreatic cancer.

Evidence suggests that CXCR2 interacts directly or indirectly with other
receptors, ion channels, transporters, scaffolding proteins, effectors, and cytoskeletal
elements to form macromolecular complexes at specialized subcellular domains

119, 152

.

These dynamic protein-protein interactions regulate CXCR2 signaling function as well as
its localization and processing within cells

176, 177

. We have shown that CXCR2,
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phospholipase C-β3 (PLCβ3), and Na+/H+ exchanger regulatory factor-1 (NHERF1) form
macromolecular complexes at the plasma membrane of pancreatic cancer cells, which
functionally couple chemokine signaling to PLCβ3-mediated signaling cascade

152

.

PLCβ3, a membrane bound enzyme, catalyzes the formation of inositol 1,4,5trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This
reaction uses calcium as a cofactor and plays an important role in the intracellular
transduction of many extracellular signals

178

. NHERF1 is a PDZ domain-containing

protein that typically functions as a scaffold to cluster transporters, receptors, and
signaling molecules into supramolecular complexes

150

. We have demonstrated that the

formation of the CXCR2-NHERF1-PLCβ3 complex is mediated by NHERF1 PDZ
domains, which bridge CXCR2 and PLCβ3 through binding to their C-terminal PDZbinding motif

152

. We also showed that disruption of this PDZ-mediated interaction

abolishes CXC signaling and inhibits tumor growth in PNAC-1 cells and also in human
PDAC xenograft animal model 152. These findings imply that targeting the PDZ-mediated
CXCR2-PLCβ3 interaction could provide new strategies for therapeutic interventions of
CXCR2-related cancers.

In general, PDZ domains mediate protein interactions by recognizing the Cterminal sequence of target proteins and binding to the targets through a canonically and
structurally conserved PDZ peptide-binding pocket 121. The specificity of the interactions
is determined mainly by the residues at positions 0 and -2 of the peptides (position 0
referring to the C-terminal residue), whereas other residues do not significantly contribute
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to the interaction

121

. This has led to the classification of PDZ domains into two major

specificity classes: class I, (S/T)X(V/I/L) (X denoting any amino acid); class II,
(F/Y)X(F/V/A)

1, 123, 124

. However, more recent evidence suggests that PDZ specificity is

unexpectedly complex, with the PDZ domain family recognizing up to 7 C-terminal
ligand residues and forming at least 16 unique specificity classes

122

. In addition, many

PDZ domains can bind to multiple ligands of different peptide classes, and single
peptides are capable of binding to distinct PDZ domains 122. This complex picture raises a
challenging problem of how PDZ domains, structurally simple protein-interaction
modules, achieve the broad substrate specificity, the nature of which still remains
obscure. In this context, we present the crystal structure of NHERF1 PDZ1 in complex
with the PLCβ3 C-terminal peptide ENTQL. The structure reveals that the PLCβ3
peptide binds to PDZ1 in an extended conformation with the last four residues making
specific side chain contacts. We also show that PLCβ3 can bind both NHERF1 PDZ1 and
PDZ2 in PDAC tumor cells, consistent with the observation that the two domains share
highly structurally conserved peptide-binding pockets. This study provides the structural
basis of the PDZ-mediated NHERF1-PLCβ3 interaction and could be valuable in the
development of novel therapeutic strategies against aggressive pancreatic cancers.

Materials and Methods
Protein Expression and Purification
For X-ray crystallography, a DNA fragment encoding the human NHERF1 PDZ1
(residues 11–94) was amplified by PCR using the full-length human NHERF1 cDNA as a
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template. The C-terminal extension ENTQL that corresponds to residues 1230–1234 of
human PLCβ3 was created by inclusion of 15 extra bases in the reverse primer. The PCR
products were cloned in the pSUMO vector containing an N-terminal His6-SUMO tag.
The resulting clone was transformed into Escherichia coli BL21 Condon Plus (DE3) cells
for protein expression. The transformants were grown to an OD600 (optical density at
600 nm) of 0.4 at 37 °C in LB medium, and then induced with 0.1 mM isopropylthio-βD-galactoside at 15 °C overnight. The cells were harvested by centrifugation and lysed by
French Press. The soluble fraction was then subjected to Ni2+ affinity chromatography
purification, followed by the cleavage of the His6-SUMO tag with yeast SUMO Protease
1. PDZ1 proteins were separated from the cleaved tag by a second Ni2+ affinity
chromatography and further purified by size-exclusion chromatography. Finally, the
proteins were concentrated to 30–40 mg/ml in a buffer containing 20 mM Tris–HCl (pH
8.0), 150 mM NaCl, 1 mM β-mercaptoethanol, and 5% glycerol. For pulldown
experiments, glutathione S-transferase (GST) fusion proteins were generated by cloning
NHERF1 PDZ1, PDZ2, or PDZ1-PDZ2 into the pGEX4T-1 vector

119

. His-S-tagged

proteins were generated by cloning PLCβ3 C-terminal fragment (residues 1135–1234)
into the pET30 vector

152

. GST-PDZ proteins were purified using glutathione agarose

beads (BD Biosciences) and eluted with 50 mM glutathione. His-S-PLCβ3 was purified
using Cobalt resins (Thermo Scientific) and eluted with 200 mM imidazole.

Crystallization, Data Collection and Structure Determination
Crystals were grown by the hanging-drop vapor-diffusion method by mixing the
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protein (~25 mg/ml) with an equal volume of a reservoir solution containing 100 mM
sodium acetate, pH 4.6, 2.5 M sodium chloride at 20 °C. Crystals typically appeared
overnight and continued to grow to their full size in 3–4 days. Prior to X-ray diffraction
data collection, crystals were cryoprotected in a solution containing the mother liquor and
25% glycerol and flash cooled in liquid nitrogen. The data were collected at 100 K at
beamline 21-ID-F at the Advanced Photon Source (Argonne, IL) and processed and
scaled using the program XDS 95. Crystals belong to the space group P3121 with unit cell
dimensions a = b = 50.7 Å, c = 66.7 Å, and one molecule in the asymmetric unit (Table
6). The structure was solved by the molecular replacement method with the program
PHASER

96

using the PDZ1-CXCR2 structure (PDB code: 4JL7) as a search model.

Structure modeling was carried out in COOT
PHENIX

97

69

, and refinement was performed with

. To reduce the effects of model bias, iterative-build OMIT maps were used

during model building and structure refinement. The final models were analyzed and
validated with Molprobity

99

. All Figureures of 3D representations of the PDZ1-PLCβ3

structure were made with PyMOL (www.pymol.org).

Cell Culture
Human PDAC cell lines (PANC-1, AsPC-1, and BxPC-3) were obtained from
American Type Culture Collection (Manassas, VA). Cells were cultured in Dulbecco’s
modified Eagle’s medium (Thermo Scientific Hyclone) containing 4.5 mg/ml D-glucose
and L-glutamine supplemented with 10% FBS, 100 units/ml penicillin, and 100 µg/ml
streptomycin at 37°C in humidified air with 5% CO2.
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Pulldown Assays
GST pulldown assays were preformed as previously described 119. Briefly, PDAC
cells were lysed in a binding buffer containing phosphate-buffered saline (PBS), 0.2%
Triton X-100, and a mixture of protease inhibitors. Supernatant was equally mixed with
GST alone or various GST-PDZ fusion domains (GST-PDZ1, GST-PDZ2, or GSTPDZ1-PDZ2) at 4 °C for 2 hours. The mixture was pulled down by glutathione agarose
beads at 4°C overnight, washed three times with the binding buffer, and then eluted in
Laemmli sample buffer containing β-mercaptoethanol. The eluents were separated by
SDS-PAGE and immunoblotted with anti-PLCβ3 antibody. To verify the direct
NHERF1-PLCβ3 interaction, purified GST-NHERF1 PDZ domains or GST alone were
mixed with a purified His-S-PLCβ3 C-terminal fragment (last 100 residues) in the
binding buffer at 20 ºC for 1 hour. The mixtures were incubated with S-protein agarose
beads for 2 hours. The beads were washed three times with the binding buffer and eluted
with Laemmli sample buffer containing β-mercaptoethanol. The eluents were resolved by
SDS-PAGE and immunoblotted with anti-His antibody. All experiments were repeated at
least three times, and the results were consistent.

Protein Data Bank Accession Number
Coordinates and structure factors have been deposited in the Protein Data Bank
with accession number 4PQW.
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Table 6. Crystallographic data and refinement statistics
Data
Space group
Cell parameters (Å)
a, b
c
Wavelength (Å)
Resolution (Å)
Rmergea
Redundancy
Unique reflections
Completeness (%)
〈I/σ〉
Refinement
Resolution (Å)
Molecules/AU
Rworkc
Rfreed
Ramachandran plot
Residues in favored
Residues in allowed
RMSD
Bond lengths (Å)
Bond angels (°)
No. of atoms
Protein
Peptide
Water
Chloride
Nickel
B-factor (Å2)
Protein
Peptide
Water
Chloride
Nickel
a

P3121
50.7
66.7
1.1272
33.3-1.47 (1.51-1.47)
0.041 (0.575)b
6.9 (6.5)
17247
99.5 (100)
21.2 (2.7)
26.6 - 1.47 (1.52- 1.47)
1
0.181 (0.276)
0.196 (0.325)
98.9%
1.1%
0.005
0.95
1334
80
93
4
1
37.5
41.2
42.7
37.7
41.0

Rmerge= Σ|I-〈I〉| / ΣI, where I is the observed intensity and 〈I〉 is the
averaged intensity of multiple observations of symmetry-related reflections.
b
Numbers in parentheses refer to the highest resolution shell.
c
Rwork= Σ|Fo-Fc| / Σ|Fo|, where Fo is the observed structure factor, Fc is the
calculated structure factor.
d
Rfree was calculated using a subset (5%) of the reflection not used in the
refinement.
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Results and Discussion
Binding specificity of NHERF1-PLCβ3 Interaction
The overall structure of NHERF1 PDZ1 is similar to other PDZ domains

1, 140

,

consisting of six β strands (β1–β6) and two α-helices (αA and αB) (Figure. 25A and B).
The PLCβ3 peptide binds in the cleft between β2 and αB, burying a total solventaccessible surface area of 382 Å2. The binding specificity of the PDZ1-PLCβ3 interaction
is achieved through networks of hydrogen bonds and hydrophobic interactions (Figure.
25C). At the ligand position 0, the side chain of Leu0 is nestled in a deep hydrophobic
pocket formed by invariant residues Tyr24, Phe26, and Leu28 from β2 and Val76 and
Ile79 from αB (Figure. 25D). In the pocket, the position of Leu0 is further secured by
both a hydrogen bond from its amide nitrogen to the Phe26 carbonyl oxygen and triplet
hydrogen bonding between the Leu0 carboxylate and the amides of Tyr24, Gly25, and
Phe26. Similar interactions have been observed in several other PDZ-mediated
complexes

1, 140

, which represent the most-conserved binding mode for terminal Leu

recognition.

Residues at other peptide positions also contribute to the PDZ1-PLCβ3 complex
formation (Figure. 25C). At the ligand position -1, the aliphatic portion of the Gln-1 side
chain makes Van der Waals interaction with the imidazole ring of His27. At position -2,
Thr-2 makes one hydrogen bond to the His72 imidazole group and two hydrogen bonds
to the highly conserved residue Leu28. At the ligand position -3, the interactions with
Asn-3 include a direct hydrogen bond from its side chain oxygen to the Nη1 atom of
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Figure 25. Structure of NHERF1 PDZ1 in complex with the PLCβ3 C-terminal sequence
ENTQL. (A) Ribbon diagram of the PDZ1-PLCβ3 structure. PDZ1 is shown in green and
the PLCβ3 peptide is shown in magenta. Secondary structures of PDZ1, α-helices, and βstrands are labeled and numbered according to their position in the sequence. (B) Surface
representation of the PDZ1-PLCβ3 structure. Surface coloring is according to the
electrostatic potential: red, white, and blue correspond to negative, neutral, and positive
potential, respectively. The vacuum electrostatics/protein contact potential was generated
by PyMOL. The PLCβ3 peptide is depicted by sticks. (C) Stereo view of the PDZ1
ligand-binding site bound to the PLCβ3 C-terminal peptide. PDZ1 residues are
represented by sticks with their carbon atoms colored in green. The PLCβ3 peptide is
depicted by sticks overlaid with 2Fo − Fc omit map calculated at 1.47 Å and contoured at
1.8 σ. Hydrogen bonds are illustrated as red broken lines. (D) Sequence alignment of
selected PDZ domains. The alignment was performed by ClustalW 3, including human
NHERF1 and NHERF2. Identical residues are shown as white on black, and similar
residues appear shaded in cyan. Secondary structure elements are displayed above the
sequences and labeled according to the scheme in Figure A. Sequence numbering is
displayed to the left of the sequences, with every 10th residue marked by a dot shown
above the alignment.
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Arg40 and a water-mediated hydrogen bond to the Nε atom of Arg40. The latter two
interactions represent ligand specific interactions, as the small side chain of Ser-3 is
recognized by His29 in PDZ1-CXCR2 complex 179, 180. Finally, the peptide residue Glu-4
engages in a main chain contact with Gly30, but does not participate in any specific side
chain interactions. These observations indicate that the last four residues of PLCβ3
contribute to the binding specificity in the PDZ1-PLCβ3 complex formation.

Endogenous PLCβ3 Interacts with Both NHERF1 PDZ1 and PDZ2
To gain further insight into the NHERF1-PLCβ3 interaction, we performed GST
pulldown assays to examine whether NHERF1 PDZ domains interact with endogenous
PLCβ3 in PDAC cells. Lysates of various PDAC cells, PANC-1, AsPC-1, and BxPC-3
were used to interact with the GST fusion proteins GST-PDZ1, GST-PDZ2, and GSTPDZ1-PDZ2. As shown in Figure. 26A, no PLCβ3 was detected in the control lane
containing GST alone, but significant amounts of PLCβ3 were found in the lanes
containing PDZ1, PDZ2, and both PDZ domains together. Similar results were observed
for all PDAC cells tested in our experiments. To check whether the PDZ-PLCβ3
interaction is direct, we performed GST pulldown assays with a purified peptide
corresponding to the last 100 amino acids of PLCβ3. We observed similar binding results
where PLCβ3 interacts with both PDZ domains of NHERF1 (Figure. 26B).

To understand the structural basis of the bivalent binding, we performed a
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Figure 26. Endogenous PLCβ3 in human pancreatic cancer cells interacts with both
NHERF1 PDZ1 and PDZ2. (A) GST pull-down of endogenous PLCβ3 with NHERF1
PDZ domains. Lysates of PDAC cells, BxPC-3, PANC-1, or AsPC-1 were used as prey.
GST fusion proteins of NHERF1 PDZ1, PDZ2, or PDZ1-PDZ2 were used as bait. GST
alone served as a negative control. Binding experiments were analyzed by SDS-PAGE
and visualized by immunoblotting using anti-PLCβ3 antibody. (B) GST pull-down assays
to detect direct interaction between purified PLCβ3 and NHERF1. A His-S-tagged
peptide corresponding to the last 100 residues of PLCβ3 was used as prey. Purified GSTPDZ1, GST-PDZ2, GST-PDZ1-PDZ2, or GST alone was used as bait. Binding was
resolved by SDS-PAGE and immunoblotted with anti-S antibody. (C) SDS-PAGE
analysis of beads-immobilized GST proteins in each above reaction (loading control).
Lane M is molecular weight markers. Molecular weights are indicated at the left of the
gel. The gel is visualized by Coomassie blue staining.

structural alignment between the structure of NHERF1 PDZ1 and the structure of
NHERF1 PDZ2. The alignment reveals that NHERF1 PDZ1 and PDZ2 share highly
similar overall structures and highly conserved ligand-binding pockets (Figure. 27). The
root mean square (rms) difference is 1.35 Å for the overall structure (86 Cα atoms), and
for the ligand-interacting residues, 0.44 Å. The only notable difference in the ligandbinding sites is residue 27, which is His in PDZ1 and Asn (residue 164) in PDZ2. It
should be noted that this conserved substitution maintains the amino functionality of the
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Figure 27. Structural comparison of NHERF1 PDZ1 and PDZ2. (A)
Superposition of the structures of PDZ1-PLCβ3 (green; PDB code: 4PQW) and
PDZ2 (gray; PDB code: 2OZF). PDZ domains are represented by ribbons.
Residues in PLCβ3 are displayed as sticks with the carbon atoms shown in
magenta. (B) Superposition of the PDZ ligand binding pockets. Both PDZ and
ligand residues are depicted by sticks and colored according to the scheme in
Figure A.
side chain, which is not expected to disrupt the observed Van der Waals contact between
PDZ1 and PLCβ3 (Figure. 25C). Therefore, the comparison of PDZ1 and PDZ2 provides
a structural explanation for the ability of PLCβ3 to bind to both PDZ domains.

Implication in Selective Drug Design
We previously have suggested that targeting the NHERF1-mediated CXCR2PLCβ3 interaction may have a therapeutic potential in PDAC treatment, as inhibition of
this interaction has been found to be sufficient to inhibit CXCR2 signaling activity both
in vitro and in vivo

152

. These findings highlight the significance of our present structure
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studies, and imply that structural details of the NHERF1-PLCβ3 interaction may be
valuable in developing new methods and strategies for selective drug design. For
instance, this information can be used to create new NHERF1 inhibitors that are potent
and specific to block the NHERF1-PLCβ3 interaction. Such inhibitors have the potential
to inhibit pancreatic tumor growth by suppressing CXCR2 signaling, and preventing
tumor cell proliferation and invasion. In addition, the ability of PLCβ3 to bind both PDZ
domains (Figure. 26), together with similar PDZ structures (Figure. 27), suggests
NHERF1 inhibitors may be capable of targeting PDZ1 and PDZ2 simultaneously. Such
inhibitors might be advantageous in cancer treatment, as PDZ1 and PDZ2 have been
shown to have differential roles during metastasis. NHERF1 PDZ2 promotes visceral
metastasis via invadopodia-dependent invasion and anchorage-independent growth, as
well as by inhibition of apoptosis; while PDZ1 promotes bone metastasis by stimulating
podosome nucleation, motility, angiogenesis, and osteoclastogenesis in the absence of
increased growth or invasion 134. It is conceivable that simultaneous targeting of the PDZ
domains could lead to a combinatorially synergetic effect that would prevent metastatic
behavior and inhibits mesenchymal-to-vasculogenic phenotypic transition in cancer
patients. While the biological impact of the bivalent NHERF1-PLCβ3 interaction is
currently unknown, future studies should be directed toward evaluation of its effect on
CXCR2-mediated PDAC proliferation and invasion, and especially toward determining
whether different PDZ domains could mediate the assembly of distinct CXCR2 signal
transduction complexes. Such studies should have important implications in specific
NHERF1 scaffolding regulation, and in many CXCR2-associated human cancers.
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Protein X-ray crystallography is a powerful approach for elucidating protein
structure and function. The high-resolution data generated by X-ray allow us to visualize
protein structures in a three-dimensional (3D) space, which is vital for our understanding
of the protein intra- and intermolecular interactions that explain the mechanisms of
various biological events. More importantly, such information can provide a structural
basis for developing new methods and strategies of targeted drug discovery. In this
dissertation, by using X-ray crystallography as the primary approach, we have performed
the structural and functional studies of SMYD2 and NHERF1 and have determined their
mechanisms of action in epigenetic regulation and protein scaffolding, respectively.
Primarily identified as a histone lysine methyltransferase, SMYD2 has been
shown to be play important roles in muscle development and tumorigenesis. In addition
to histone substrate, SMYD2 can also methylate non-histone proteins including p53,

167

retinoblastoma tumor suppressor and estrogen receptor alpha. However, there are still
many gaps in knowledge regarding the mechanisms underlying the activity regulation
and substrate recognition of SMYD2. In this dissertation, we solved the crystal structures
of SMYD2 with two different cofactors. Both cofactor-bound SMYD2 structures have a
two-lobed structure with the active site partially blocked by a domain at the C-terminus
(CTD). Although the two structures are highly superimposable, detailed structural
analysis revealed the significantly different CTD conformations, suggesting the CTD
flexibility that may be involved in the regulation of SMYD2 histone methyltransferase
activity. In addition, the structural similarity between the CTD and the tetratricopeptide
repeats (TPR) suggests a possible mechanism for the Hsp90-mediated SMYD activity
enhancement. Based on such knowledge, we then employed the co-crystallization
approach to study the mechanisms for the substrate recognition. We have successfully cocrystallized SMYD2 with a non-histone substrate, estrogen receptor alpha (ERα). The
complex structure revealed that ERα peptide binds SMYD2 in a U-shaped conformation
with the binding specificity determined predominantly by residues C-terminal to the
target lysine. The structure also showed that the broad specificity of SMYD2 is achieved
by multiple molecular mechanisms such as distinct peptide binding modes and the
intrinsic dynamics of peptide ligands. Interestingly, a novel potentially SMYD2-specific
PEG binding site is identified in the CTD, implicating possible functions in additional
substrate binding or protein-protein interactions.
The formation of CXCR2−NHERF1−PLCβ macromolecular complex plays vital
roles in both inflammation and pancreatic cancers. In neutrophils, this NHERF1-mediated
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macromolecular complex is essential in intracellular calcium mobilization and neutrophil
migration. In pancreatic cancer cells, this complex regulates tumor proliferation and
invasion. Therefore, targeting this NHERF1-mediated macromolecular complex will have
great clinical importance. The second objective of this dissertation is to provide the
structural basis for the formation of this NHERF1-mediated macromolecular complex. To
achieve this, we first solved the complex structures of the NHERF1 PDZ1 domain with
the C-terminal sequence of CXCR2 in two different crystal forms. Although the
superposition revealed a high degree of overall structural similarity, distinct
conformations were observed between the two forms in substrate-binding pocket and
bound peptide. These conformational differences indicated that the flexibility of the
ligand-binding pocket might be required for diverse peptide recognition. The structural
comparison also reveals that the intrinsic dynamics of the peptide ligand may allow the
PDZ1 domain for interactions with different peptide recognition residues.
The interactions between NHERF1 and the CXCR2 downstream effector PLCβ3
have been studied using the same strategy as mentioned above. The structural studies of
the PDZ1−PLCβ3 complex allowed us to identify the determinants of the PDZ1 binding
specificity. We also showed that PLCβ3 can bind PDZ2 in pancreatic cancer cells,
consistent with the observation that the peptide binding pocket of these PDZ domains are
highly structurally conserved.
In summary, the studies preformed in this dissertation have revealed new insights
into the mechanisms behind the lysine methylation machinery and protein scaffolding
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which are central to many biological processes and diseases. Such findings will be of
great benefit in the development of alternative therapeutic strategies and drug design.
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